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ABSTRACT 
 
 T cell vaccines against Mycobacterium tuberculosis (Mtb) and other 
pathogens are based on the principle that memory T cells rapidly generate effector 
responses upon challenge, leading to pathogen clearance. Despite eliciting a 
robust memory CD8+ T cell response to the immunodominant Mtb antigen TB10.4 
(EsxH), we find the increased frequency of TB10.4-specific CD8+ T cells conferred 
by vaccination to be short-lived after Mtb challenge. To compare memory and 
naïve CD8+ T cell function during their response to Mtb, we track their expansions 
using TB10.4-specific retrogenic CD8+ T cells. We find that the primary (naïve) 
response outnumbers the secondary (memory) response during Mtb challenge, an 
effect moderated by increased TCR affinity. To determine whether the expansion 
of polyclonal memory T cells is restrained following Mtb challenge, we used TCRb 
deep sequencing to track TB10.4-specific CD8+ T cells after vaccination and 
subsequent challenge in intact mice. Successful memory T cells, defined by their 
clonal expansion after Mtb challenge, express similar CDR3b sequences 
suggesting TCR selection by antigen. Thus, both TCR-dependent and 
independent factors affect the fitness of memory CD8+ responses. The impaired 
expansion of the majority of memory T cell clonotypes may explain why some TB 
vaccines have not provided better protection.  
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CHAPTER I  
 
Introduction 
 
Mycobacterium tuberculosis infection 
Tuberculosis (TB) is the deadliest infectious disease in human history, 
recently surpassing HIV in the number of deaths attributable to disease (World 
Health Organization, 2015). Mycobacterium tuberculosis (Mtb), the acid-fast 
bacterium that causes TB, infects one third of the world’s population and kills 1.5 
million people per year (World Health Organization, 2015). Mtb is transmitted from 
person to person through the inhalation of aerosol droplets. Droplets containing 
the bacteria reach alveoli in the distal lung where they primarily infect resident 
alveolar macrophages (J. Lee et al., 2009; Leemans et al., 2001) (Fig 1.1). The 
initial stages of infection are characterized by an innate immune response that 
includes the recruitment of inflammatory cells to the lung. However, the initiation 
of adaptive immunity is delayed compared to pathogens that cause acute infection, 
and occurs only after dissemination of M. tuberculosis to draining lymph nodes 
(Chackerian et al., 2002; Reiley et al., 2008; Wolf et al., 2008).  
In the lymph node, presentation of bacterial antigens by dendritic cells leads 
to priming and expansion of antigen-specific T cells (Chackerian et al., 2002; 
Reiley et al., 2008; Wolf et al., 2008). During this process, naïve T cells differentiate 
into effector T cells, which then migrate to the infected lung. The recruitment of 
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immune T cells, in combination with other leukocytes leads to granuloma 
formation, a hallmark of tuberculosis. Macrophages in granulomas, with support 
from other macrophages and T cells, attempt to kill mycobacteria using oxidative 
damage in phagolysosomes, the induction of apoptosis, autophagy and 
efferocytosis (Divangahi et al., 2013; Hartman and Kornfeld, 2011; C. J. Martin et 
al., 2012; Molloy et al., 1994; Moraco and Kornfeld, 2014; Oddo et al., 1998). 
Overall, granulomas are thought to contain Mtb, restrict its dissemination, and 
prevent replication. However, some evidence suggests that the local spread of 
actively dividing mycobacteria is facilitated during early granuloma formation 
(Cambier et al., 2014; J. M. Davis and Ramakrishnan, 2009; Ramakrishnan, 2012). 
Infection with Mtb is followed either by immune control of bacterial growth and the 
development of latency, or progression to active pulmonary tuberculosis (Fig 1.1).  
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Figure 1.1: TB pathogenesis. Infection is initiated by the inhalation of aerosol droplets 
that contain bacteria. The initial stages of infection are characterized by innate immune 
responses that involve the recruitment of inflammatory cells to the lung. Following bacterial 
dissemination to the draining lymph node, dendritic cell presentation of bacterial antigens 
leads to T cell priming and triggers an expansion of antigen-specific T cells, which are 
recruited to the lung. The recruitment of T cells, B cells, activated macrophages and other 
leukocytes leads to the establishment of granulomas, which can contain Mycobacterium 
tuberculosis. Most infected individuals will remain in a ‘latent’ state of infection, in which 
no clinical symptoms are present. A small percentage of these people will eventually 
progress and develop active disease, which can lead to the release of M. tuberculosis 
from granulomas that have eroded into the airways. When individuals with active 
tuberculosis cough, they can generate infectious droplets that transmit the infection.  
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Active pulmonary TB is characterized by the development of a chronic 
pneumonia that progresses over a period of months to years, accompanied by 
fevers, night sweats, weight loss, productive cough, and, frequently, hemoptysis. 
In some cases, Mtb disseminates to other organs via the bloodstream, causing 
meningitis, enteritis, pyelonephritis, and occasionally infiltrates the bones and 
marrow (Kato-Maeda et al., 2016). The sequelae of TB dissemination are 
particularly lethal and disfiguring. However, those with a healthy immune system 
that control pulmonary TB early after inoculation develop latent disease and have 
a 5-20% lifetime risk of reactivation (Horsburgh, 2004). The risk of reactivation and 
the development of active pulmonary tuberculosis is greatest in the first 2 years 
after infection (Horsburgh, 2004). Patients with newly-diagnosed, latent TB are 
typically treated with antibiotics for 4-9 months in an attempt to eradicate 
sequestered mycobacteria and reduce the risk of reactivation disease (Horsburgh 
and Rubin, 2011). 
The treatment of tuberculosis requires the use of multiple antibiotics for at 
least 6 months once active disease ensues (Zumla et al., 2015). Complications 
such as drug-resistance or intolerance can limit the use of many effective regimens 
(Velayati et al., 2009; S. Wu et al., 2013). Antibiotic resistance has made some 
cases of TB impossible to treat (Velayati et al., 2009), and mainstream 
international travel is leading to the rapid spread of extensively drug-resistant Mtb 
strains. The extreme social and economic burden of TB, the difficulty in completion 
of treatment regimens, and the risk of antibiotic-resistant infection highlight the 
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need not only for more effective antibiotics, but for the development of an effective 
TB vaccine.  
 
The delayed onset of adaptive immunity 
The delay in initiating T cell responses in the Mtb-infected is the most 
significant limitation in the ability of T cells to protect the host from TB, and may 
also be hindering protective vaccination. A delay in the adaptive immune response 
to Mtb was first observed in early studies of household contacts of TB patients. 
Tuberculin skin test (TST) responses were tested weekly in the household contacts 
of patients diagnosed with active pulmonary TB in Scandinavia in the early 1930s 
(Stewart, 1956; Wallgren, 1948). Those who converted to a positive TST did so 3 
– 6 weeks after close contact with an Mtb- infected individual. Although difficult to 
determine the exact time of inoculation, these data also likely underrepresent the 
time required to convert their skin test: As patients diagnosed with TB were likely 
to already be contagious prior to their diagnosis, their delay in the development of 
adaptive immunity (newly positive TST) is considerable.  
Several animal studies have also shown that adaptive immunity in the lung 
is delayed nearly 2 weeks after inoculation of mice. Three landmark studies 
showed that T cells are first primed in the lung-draining mediastinal lymph nodes 
(MLN), where actively-dividing mycobacteria must first be transported, prior to 
responding to infection in the lung (Chackerian et al., 2002; Reiley et al., 2008; 
Wolf et al., 2008). Initiation of T cell responses in the MLN (9 - 11 days post-
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infection) are followed by T cell trafficking to the lung (d12 – 14). In addition to its 
relevance to priming naïve T cells that target Mtb-infected cells, Jung et al. have 
shown that memory T cells responding to aerosol Mtb challenge also experience 
a delay in their response to infection (Jung et al., 2005). The delay in priming a 
primary (or secondary) adaptive immune response to Mtb may be one of the most 
important limitations in our immune system’s ability to reliably prevent or eradicate 
Mycobacterium tuberculosis infection. A successful TB vaccine will likely need to 
drive earlier T cell responses in order to be effective. 
 
Current TB vaccines 
Vaccines have proven to be the most cost-effective intervention against 
infectious diseases in history, yet the development of a vaccine that reliably 
prevents tuberculosis has eluded scientists for nearly a century. Classic vaccine 
approaches using heat-killed or live-attenuated pathogens have almost exclusively 
been used to generate protective antibodies- relying on the immune system to 
develop memory B cell (and likely CD4+ T cell) responses targeting a broad array 
of antigens (Plotkin, 2010). However, the protection conferred by memory T cells 
elicited by vaccination with an attenuated pathogen has been disappointing for TB. 
Natural immunity to TB can be modeled in mice by clearing primary infection with 
antibiotics (Jung et al., 2005). Upon re-challenge with aerosolized Mtb, a 10-fold 
CFU reduction is observed but the host remains chronically-infected. Furthermore, 
protection is short-lived and is accompanied by little or no change in survival (Jung 
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et al., 2005; Kamath and Behar, 2005). Vaccines tested in animal models have 
displayed a similar pattern of early control of CFU but rarely achieve prolonged 
survival after Mtb infection, and certainly have failed to provide sterilizing immunity 
(Henao-Tamayo et al., 2014; Nunes-Alves et al., 2014; Ottenhoff and Kaufmann, 
2012). 
BCG, an attenuated strain of Mycobacterium bovis, is the only approved TB 
vaccine, used widely outside of the U.S. However, its ability to prevent active 
pulmonary disease is inconsistent and appears to be particularly ineffective in 
countries with a high TB incidence (Brewer, 2000; Brewer and Colditz, 1995; Fine, 
1995). In a recent, double-blind phase 2b clinical trial, a novel TB vaccine 
(MVA85A), used as a boost to BCG vaccination in South African children, did not 
prevent active pulmonary TB (Tameris et al., 2013). Convincing animal and 
epidemiologic data has shown that both helminth infection (Elias et al., 2008; Fine, 
1995) and exposure to environmental non-tuberculous mycobacteria (NTM) 
(Collins, 1971; Palmer and Long, 1966; Youmans et al., 1961) in areas endemic 
with TB are potential confounders to the protection attributed to BCG vaccine 
efficacy (Black et al., 2001; Brandt et al., 2002; Elias et al., 2008). However, such 
confounders would not explain the overall high rates of tuberculosis in endemic 
areas despite environmental NTM exposure, BCG vaccination, or prior Mtb 
infection, all of which elicit T cells specific for mycobacterial antigens in the infected 
host. Furthermore, a large retrospective study recently described that individuals 
successfully treated for active TB are not protected from reinfection (Millet et al., 
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2013). In this study, patients diagnosed with recurrent TB were estimated to have 
an increased risk of re-exposure to infection. Furthermore, in half of the patients 
whose Mtb isolates were genotyped, a new isolate was found to be causing re-
infection. Although both vaccination and prior infection elicit antigen-specific 
memory T cells that control or prevent infection by many other pathogens, memory 
T cells, in general, have not shown the same protective function against Mtb. 
Therefore, to generate a more effective TB vaccine design, these data indicate the 
need to better understand what constitutes protective memory T cell responses for 
TB. 
 
Protective memory T cell responses 
The goal of T cell vaccination is to establish pre-existing immunity against 
pathogens in the form of memory T cells. Two features of memory T cells make 
them superior to naïve T cells in mediating protection: First, memory T cells have 
undergone a cycle of expansion and contraction, leading to a greater frequency of 
pathogen-specific T cells than are present among the naïve T cell repertoire. 
Second, memory T cells do not classically require “priming” and rapidly express 
effector activity after antigen recognition, even after presentation by non-
professional APCs. These features, together with their long-lived nature and their 
ability to survey non-lymphoid organs allow memory T cells to quickly respond to 
acute infection (Ahmed and Gray, 1996; Jameson and Masopust, 2009; Swain et 
al., 1991; 1990; Vitetta et al., 1991).  
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Memory T cells are generated after vaccination or prior infection of the host. 
Interestingly, Mtb vaccines show little evidence of long-lived protection, even in 
mouse models (Orme, 2006), despite 5–10 fold reductions in bacterial burden early 
after aerosol infection (Henao-Tamayo et al., 2014). These results imply an early 
but transient benefit to memory T cells after Mtb challenge. Furthermore, despite 
the development of memory T cells following treatment of active TB, observations 
of those cured by antibiotics show that they are not protected from reinfection 
(Crofts et al., 2010; Millet et al., 2013; Verver et al., 2005). Although we have some 
understanding of the fate of memory T cell responses against pathogens that 
cause chronic infections, such as LCMV clone-13, a model pathogen that causes 
chronic infection in mice (Vezys et al., 2006; West et al., 2011), little is known about 
the relative contribution of naïve and memory T cells (and the resulting 1° and 2° 
responses, respectively) to the recall response elicited by the human pathogen 
Mycobacterium tuberculosis (Mtb).  
The ability to identify protective memory T cell responses elicited by 
vaccination would significantly accelerate TB vaccine design. Studies in mice have 
proven that interferong (IFNg) produced by T cells is critical for attenuating Mtb 
growth (Flynn et al., 1993; Wolf et al., 2008), however, IFNg levels have not 
successfully predicted protection against TB. In fact, prospective studies of BCG 
vaccination in mice reported that increased numbers of IFNg-secreting T cells were 
a better correlate of TB disease burden than of protection (Mittrücker et al., 2007). 
Similarly, an increase in IFNg-secreting T cells were found to predict the latent TB 
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patients most likely to progress to active disease (Diel et al., 2011). At least one 
study associates “polyfunctional” CD4+ T cells (secreting 2 or more T-helper type 
1 (Th1) cytokines) with protection against TB, by evaluating these T cell functions 
in patients with active TB over their course of treatment (Sutherland et al., 2010). 
However, confounders included differences in the activation states of the T cells 
that were compared, the effect of HIV on T cell function, the use of peptide 
stimulation in the quantification of cytokines, and the low frequencies of T cells 
found to secrete cytokines. A well-controlled study in mice comparing T cells 
elicited by a series of TB vaccines also did not find increased numbers of 
polyfunctional memory T cells to correlate with the ability to control Mtb growth 
(Tchilian et al., 2009). Finally, the MVA85A study group suggested that IFNg 
secretion (McShane et al., 2004) and polyfunctional T cells (Scriba et al., 2010) in 
vaccinated individuals were markers that herald a protective response by vaccine-
elicited T cells. However, this vaccine was not able to reduce the incidence of 
active TB in vaccinated individuals (Tameris et al., 2013). A transcriptional 
signature of host gene expression associated with risk for active TB in latently-
infected individuals was recently published (Zak et al., 2016). These hits were 
determined from RNAseq of PBMCs obtain from the blood of latent TB cases and 
control patients, followed to determine which would develop active TB. Although 
these markers negatively correlated with protection, data such as these give us a 
better understanding for how markers of immune function can reveal a detrimental 
response or correlate with protection during TB.  
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The role of CD8+ T cells in tuberculosis 
The adaptive immune response to Mtb is comprised predominantly of a T 
helper type 1 (Th1) cytokine response, as most CD4+ T cells elicited by infection 
secrete IFNγ (Fig 1.2a). CD8+ T cells have also been shown to be essential for 
optimal control of Mtb infection (Behar et al., 1999; C. Y. Chen et al., 2009; Flynn 
et al., 1992; Lin and Flynn, 2015; Mogues et al., 2001), in addition to the impact of 
CD4+ t cells in the host defense against TB. Although the survival impact on mice 
depleted of CD8+ T cells is more modest than CD4+ T cell depletion during Mtb 
infection (Mogues et al., 2001), we do not yet know which T cell subsets or 
functions are most important for a protective TB vaccine. CD8+ T cells are prime 
vaccine candidates for the prevention of disease since they are already believed 
to enforce latency in humans (Bruns et al., 2009; van Pinxteren et al., 2000), and 
play a larger role in protective immunity in non-human primate models (C. Y. Chen 
et al., 2009) compared with mouse models of infection.  
In addition to cytokine production, CD8+ T cells, have the capacity to kill 
cells that they recognize. In contrast to NK cell mediated killing, T cell killing is 
generally TCR-dependent. CD8+ T cells with the capacity to kill target cells are 
called cytotoxic T lymphocytes (CTLs). CD8+ T cells are elicited during Mtb 
infection in people and animal models and these CD8+ T cells behave as CTLs in 
vivo (Kamath et al., 2004). There exist three dominant molecular pathways that 
mediate CTL activity: 1) cytotoxic granule exocytosis; 2) Fas/FasL (CD95/CD95L); 
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and 3) TNF secretion (Fig 1.2b). All three of these mechanisms are used in a 
hierarchical manner to kill target cells in M. tuberculosis infected mice (Woodworth 
et al., 2008). The increased susceptibility of Fas / , FasL /  and perforin /  mice to 
M. tuberculosis corroborate the importance of these pathways for immunity (Turner 
et al., 2001; Woodworth et al., 2008). Importantly, perforin is required for protection 
mediated by CTLs (Woodworth et al., 2008). Human CD8+ T cells require perforin 
to restrict M. tuberculosis growth in vitro, with granulysin being an important 
granule constituent (Stenger et al., 1998). Other than perforin, the crucial effector 
molecules for murine CD8+ T cells are unknown. All three killing mechanisms used 
by CTLs induce target cell apoptosis, which is associated with reduced bacterial 
viability (Behar et al., 2010). Following apoptosis, the engulfment of apoptotic, 
infected cells by uninfected macrophages – a process known as efferocytosis – 
targets bacteria trapped in the phagocytosed apoptotic cell (the ‘efferosome’) to 
lysosomes, which leads to killing of M. tuberculosis (Hartman and Kornfeld, 2011; 
C. J. Martin et al., 2012; 2014). 
In addition to their ability to directly kill Mtb-infected cells and secrete 
cytokines in response to antigen presented by class I MHC, CD8+ T cells can 
recognize infected cell types other than professional APCs, such as lung epithelial 
cells (Harriff et al., 2014). Furthermore, CD8+ T cell responses are an important 
measure of the protective capacity of new vaccines in clinical trials (Kagina et al., 
2014; Penn-Nicholson et al., 2015). The recent lack of protection found in clinical 
trials using MVA85A or M. bovis BCG vaccines, primarily eliciting CD4+ T cell 
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responses, highlights our need to consider the importance of alternate T cell 
subsets and antigens in vaccine design (Lin and Flynn, 2015; Orme, 2006; Tameris 
et al., 2013).  
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Figure 1.2: Paradigms of protective immunity to TB. (a) The ‘central dogma’ of 
protective immunity to tuberculosis (TB) is that CD4+ T cells produce interferon-γ (IFNγ) 
(T helper 1 (TH1) cells), which synergizes with tumor necrosis factor (TNF; produced by 
the T cell or the macrophage), and together these activate macrophage antimicrobial 
activity that is capable of restricting the growth of Mycobacterium tuberculosis. Two path-
ways activated by IFNγ that are capable of killing M. tuberculosis are nitric oxide 
production and phagosome-lysosome fusion, which acidifies the bacterial phagosome. (b) 
‘A revised view of T cell-mediated immunity’ incorporates additional T cell subsets (CD4+ 
T cells, CD8+ T cells and unconventional T cells: γδ T cells, mucosal-associated invariant 
T (MAIT) cells and CD1-restricted T cells) and includes additional mechanisms by which 
T cells mediate killing of M. tuberculosis. These include additional cytokines (for example, 
granulocyte–macrophage colony-stimulating factor (GM-CSF)) and cytolysis of infected 
macrophages. The cytolytic mechanisms vary and can include cytotoxic granules, which 
can deliver antimicrobial peptides, such as granulysin, but can also deliver granzymes, 
which can trigger apoptotic cell death. Cytotoxic T lymphocyte (CTL) activity mediated by 
FAS ligand (FASL)-FAS or TNF can also lead to apoptosis. Apoptosis can have a 
beneficial effect on the outcome of infection, as infected apoptotic cells can be engulfed 
by bystander macrophages, which are capable of destroying the apoptotic cells, including 
any intracellular bacteria. Finally, several components of the innate response, including 
interleukin-1 (IL-1) and vitamins, can synergize with cytokines that are produced by T cells. 
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The TB10.4-specific CD8+ T cell response  
The Mycobacterium tuberculosis genome contains hundreds of epitopes 
that have the potential for recognition by CD8+ T cells (Blythe et al., 2007). The 
CD8+ T cell response against Mtb is heavily focused on the secreted protein 
antigen TB10.4 (EsxH; Rv0288) in people and experimentally infected animals 
(Axelsson-Robertson et al., 2013; 2010; Billeskov et al., 2007; Hoang et al., 2009; 
Majlessi et al., 2003; Woodworth et al., 2011). Following aerosol infection of 
C57BL/6 mice, 30-50% of the responding CD8+ T cells in the lungs recognize the 
H2-Kb-restricted epitope TB10.44 11, defining it as an immunodominant epitope 
(Billeskov et al., 2007; Carpenter et al., 2016; Nunes-Alves et al., 2015; Woodworth 
et al., 2008). Although we have found CD8+ T cells specific for TB10.44 11 to lower 
bacterial burdens in T cell deficient mice aerosol-infected with Mtb (Carpenter et 
al., 2016; Nunes-Alves et al., 2015), vaccination against this epitope alone has not 
yielded protection (Carpenter et al., 2016; Lindenstrøm et al., 2014). One caveat 
to the study of CD8+ T cells during TB is the difficulty in distinguishing protective 
from non-protective CD8+ T cells specific for individual antigens. The reason for 
this is that the ability of individual groups of antigen-specific CD8+ T cells to reduce 
Mtb bacterial burden is dwarfed by that of CD4+ T cells, and the rest of the primary 
immune response as a whole, during the first few months after infection. On the 
other hand, generating T cells in mice (ie. vaccination, adoptive transfer) that elicit 
a modest reduction in bacterial CFUs four weeks after Mtb challenge does not 
always correlate with prolonged survival (Jung et al., 2005; Kamath and Behar, 
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2005), or improvement in disease burden. Therefore, the discovery of new 
functional markers of protective T cells is critical, and applies equally to CD8+ and 
CD4+ T cells during TB.  
 
The antigen-specific T cell receptor (TCR) repertoire 
The adaptive immune system has the capacity generate >1015 unique TCRs 
(M. M. Davis and Bjorkman, 1988; Sewell, 2012), enabling the recognition of an 
enormous set of distinct foreign (and self) peptide antigens (Jenkins et al., 2010; 
Venturi et al., 2008). The TCR repertoire found in each individual are selected in 
the thymus from the presentation of peptides on their unique repertoire of major 
histocompatibility complex (MHC) molecules (M. M. Davis et al., 1998). Of the vast 
number of possible unique TCRs, only a subset are represented in the 
approximately 107-108 (mouse) and 1011-1012 (human) total T cells within each 
individual (Arstila et al., 1999; Casrouge et al., 2000; Jenkins et al., 2010). Of 
these, approximately 2x106 (mouse) (Casrouge et al., 2000; Jenkins et al., 2010) 
and 1x108 (human) (Arstila et al., 1999) T cells are calculated to be unique clones 
containing distinct complementarity-determining 3 (CDR3) sequences. In the 
mouse, this estimate indicates an average of ~30 copies of each antigen-specific 
T cell clone, and between 5 - 500 unique naïve precursor clones specific for a 
particular antigen (Casrouge et al., 2000; Jenkins et al., 2010). As discussed in 
Chapter 3, this is particularly relevant to tracking the frequency of memory and 
naïve T cells specific for Mtb antigens, especially CD8+ T cells specific for the 
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TB10.4 antigen. In fact, we have previously estimated the naïve precursor 
frequency in C57BL/6 mice to be ~800 T cells per mouse, which is relatively high 
at ~1 of every 20,000 CD8+ T cells (Nunes-Alves et al., 2015). This frequency is 
within the range estimated by others of the naïve precursor frequencies in mice for 
various antigens: B8R (vaccinia virus), ovalbumin, and antigens from HSV-1 and 
LCMV, range from ~15 – 1100 naïve T cell precursors per mouse (Haluszczak et 
al., 2009; Jenkins et al., 2010; Kotturi et al., 2008; Obar et al., 2008). Based on 
work studying the factors that lead to antigenic immunodominance (W. Chen et al., 
2001; Kotturi et al., 2008; Moon et al., 2007; Yewdell, 2006; Yewdell and Del Val, 
2004), high precursor frequency is likely a major contributor to the 
immunodominance of TB10.4 among Mtb antigens. 
Despite significant knowledge of antigen recognition and the genetic and 
structural basis for TCR diversity, we have a relatively primitive understanding of 
the forces behind the magnitude and diversity of T cell responses to microbial 
antigens. The pathogen-specific T cell response usually focuses on a small 
number of the available antigenic epitopes, and uses a narrow TCR repertoire 
(Jenkins and Moon, 2012; Kotturi et al., 2008; Moon et al., 2007; Yewdell, 2006). 
Pathogens have numerous strategies to evade host immunity, hindering our ability 
to determine how T cell diversity relates to antimicrobial immunity. For pathogens 
that rapidly mutate, such as the Human Immunodeficiency Virus (HIV), a diverse 
T cell response could benefit the host by efficiently detecting escape mutants, 
while a biased response could be detrimental. For slowly replicating pathogens, 
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that encode numerous antigens, such as Mtb, the relationship between diversity 
and protection is less clear.  
While TCR diversity serves to characterize a population of T cells 
responding to immunodominant microbial antigens, TCR affinity can be used to 
attribute function to individual CDR3 amino acid sequences when exposed to 
similar amounts of antigen presented by MHC molecules. TCR affinity affects both 
the strength of the TCR : peptide-MHC (pMHC) interaction, as well as the “dwell-
time” of peptide-MHC complexes of both CD4+ and CD8+ T cells (Aleksic et al., 
2010; Govern et al., 2010; Tubo et al., 2013). For the purpose of this dissertation, 
“dwell-time” and “confinement time” will be used interchangeably, defined here as 
the cumulative time the TCR and pMHC are engaged during an interaction that 
has the potential to activate the T cell. TCR affinity can govern the function of 
individual T cell clonotypes, and therefore affect protective capacity, not only due 
to the strength of its interaction with pMHC (measured as KD), but by its effect on 
the dwell-time of the TCR : pMHC interaction (Aleksic et al., 2010; Govern et al., 
2010; Tubo et al., 2013). TCR affinity and dwell-time appear to play a larger role 
in governing T cell function under conditions of low or limiting antigen (Vanguri et 
al., 2013). While there is little definitive data in tuberculosis, we have associated 
both high- and intermediate-affinity naïve TB10.4-specific CD8+ T cell clonotypes 
with control of bacterial growth, but have found significantly greater expansion of 
the high-affinity T cells during infection (Nunes-Alves et al., 2015). Gallegos et al., 
however, report no benefit to higher-affinity CD4+ T cells specific for another Mtb 
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antigen (ESAT-6) (Gallegos et al., 2016). Although the two T cell subsets, and 
antigens, are different, the almost certainly greater abundance of the latter antigen 
(Skjøt et al., 2000; 2002) likely plays a prominent role in determining the conditions 
for which increased TCR affinity and TCR-pMHC dwell-time kinetics play the 
greatest role (Vanguri et al., 2013).  
In addition to TCR structure, other factors appear to regulate the activation 
of memory CD8+ T cells. In addition to TCR-pMHC affinity and kinetics, antigen 
availability has been recently shown to exert a strong influence over CD8+ T cell 
activation (Mehlhop-Williams and Bevan, 2014). Whether differences in TCR 
structure and antigen availability affect the ability of memory T cells to control 
tuberculosis is unknown. We observe differences in the function of memory (and 
secondary effector) CD8+ T cells that are dependent on the affinities of their TCRs. 
Using a combination of adoptive transfer of TCR retrogenic CD8+ T cells specific 
for TB10.44 11 (TB10Rg3 and TB10Rg4) (Nunes-Alves et al., 2015) and TCRb 
deep sequencing of tetramer+CD8+ T cells after vaccination, and Mtb-challenge, in 
intact mice, we track primary (1°, those expanding from naïve T cells) and 
secondary (2°, from memory precursors) TB10.4-specific CD8+ T cells during 
infection. Compared with naïve CD8+ T cells, we observe that memory CD8+ T 
cells exhibit a decreased sensitivity to antigen that impairs their ability to expand 
in response to antigenic stimulation during tuberculosis. As a result, memory CD8+ 
T cells are unable to efficiently expand, compared with the primary response, 
making vaccine-elicited T cells unable to substantially contribute to host protection 
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in the first 2-3 weeks after aerosol Mtb challenge. Based on the data presented in 
the following chapters, I propose that the TCR affinity of memory T cells correlates 
with their capacity to protect the host from TB. An inability to compete with the 
primary immune response to Mtb is a major limitation; I argue that this mechanism 
limits their contribution to counter Mtb infection. These data imply that generating 
higher-affinity memory T cells could improve TB vaccine design. Furthermore, the 
use of memory T cell expansion after Mtb challenge may be a useful benchmark 
for identifying protective TB vaccine candidates during vaccine development.  
  
	 	 	 21	
Preface to Chapter II 
 
This chapter has been adapted from the recently published manuscript: 
Carpenter, S. M., Nunes-Alves, C., Booty, M. G., Way, S. S., & Behar, S. M. 
(2016). A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness 
Cost That Is Modified by TCR Affinity during Tuberculosis. PLoS Pathogens, 
12(1), e1005380. http://doi.org/10.1371/journal.ppat.1005380 
 
With additional data (including Figure 2.10) included from: 
Nunes-Alves, C., Booty, M. G., Carpenter, S. M., Rothchild, A. C., Martin, C. J., 
Desjardins, D., Steblenko K., Kløverpris H.N., Madansein R., Leslie A., Correia-
Neves M., Behar S. (2015). Human and Murine Clonal CD8+ T Cell Expansions 
Arise during Tuberculosis Because of TCR Selection. PLoS Pathogens, 11(5), 
e1004849. http://doi.org/10.1371/journal.ppat.1004849 
 
The exact figures and their organization are different from those in the published 
manuscripts, and additional data are included here. This manuscript represents 
the first part of the main thesis project of Stephen Carpenter, who designed and 
performed the experiments, analyzed the data, and wrote the manuscript with 
contributions from co-authors and mentorship from Dr. Samuel Behar.  
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CHAPTER II 
 
A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness Cost 
That Is Modified By TCR Affinity During Tuberculosis 
 
Introduction 
A TB vaccine is urgently-needed for the prevention of active tuberculosis. 
TB10.4 (EsxH, Rv0288) is an immunodominant Mtb antigen recognized by human 
(Axelsson-Robertson et al., 2010) and murine (Woodworth et al., 2008) CD8+ T 
cells. TB10.4 is already being tested in clinical trials (Geldenhuys et al., 2015) as 
a TB vaccine candidate since it is an essential gene and a secreted protein antigen 
of Mtb (Sassetti et al., 2003). TB10.4-specific CD8+ T cells account for 30-50% of 
all CD8+ T cells in the lungs of infected C57BL/6 and BALB/c mice. TB10.4-specific 
CD8+ T cells can confer protection against Mtb after adoptive transfer into mice 
lacking ab T cells (Nunes-Alves et al., 2015), indicating that cells of this antigen 
specificity have the ability to attenuate bacterial growth. Although the protective 
capacity of antigen-specific CD8+ T cells is difficult to distinguish among the 
dominant CD4+ T cell response in intact mice, T cell vaccination that elicited a 
robust TB10.4-specific CD8+ T cell response did not protect mice from tuberculosis 
(Lindenstrøm et al., 2014). We find that TB10.4-specific memory CD8+ T cells 
elicited by vaccination undergo early and robust expansion after aerosol Mtb 
challenge, however the number of TB10.4-specific CD8+ T cells is similar to that 
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of unvaccinated mice within four weeks. Using TCR retrogenic CD8+ T cells, we 
compare naïve and memory CD8+ T cells expressing the same TCR and observe 
that both the 1o (naïve) and the 2o (memory) CD8+ T cell responses are initiated in 
the draining lymph node at ~d11 post-infection. Following the activation of the 
TB10.4-specifc CD8+ T cells, the 2° effector response does not rapidly expand in 
response to infection, but initially has the same kinetics as the 1° response. As the 
T cells are recruited to the lung, we also observe the 2° response becomes 
outnumbered 99:1 by a highly-proliferative 1° response, indicating that TCR-
independent factors cause the memory-recall response to be less fit than the 
primary response during chronic infection. As we observe 2° effector CD8+ T cells 
to have a reduced proliferative response, particularly in chronic, low antigen 
settings, we speculate that effective T cell vaccines for tuberculosis will need to 
elicit high affinity TCRs and respond earlier than the primary response to infection. 
 
Results 
Vaccination elicits TB10-specific memory CD8+ T cells that expand after 
Mtb challenge. 
Vaccination with the peptide epitope TB10.44 11 (TB10), anti-CD40 mAb and 
poly(I:C), a vaccination strategy used in multiple infection and tumor models 
(Ahonen et al., 2004; Cho and Celis, 2009; S. Lee et al., 2012; Phoolcharoen et 
al., 2011), generates a large number of TB10-specific memory CD8+ T cells in 
C57BL/6 mice. Boosting leads to an additional 10-fold expansion such that TB10-
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specific CD8+ T cells comprise ~10% of circulating CD8+ T cells (Fig 2.1a). Eight 
weeks after boosting, 1.5-2% of the circulating CD8+ T cells are specific for TB10 
(Fig 2.1b). As described, this vaccine formulation represents a powerful and simple 
strategy to elicit high-frequency memory CD8+ T cell responses to multiple different 
tumor and viral epitopes under inflammatory conditions, and the T cells it 
generates are potent CTLs shown to eradicate melanoma lung metastases, and 
lower viral loads in both Ebola and RSV model infections (Ahonen et al., 2004; 
Cho and Celis, 2009; S. Lee et al., 2012; Phoolcharoen et al., 2011). The TB10 
tetramer+CD8+ T cells elicited one week after priming are predominantly 
KLRG1 oIL-7Rh , the phenotype of memory precursor effector cells (MPECs) (Joshi 
et al., 2007; Kaech et al., 2003). After boosting, ~50% express KLRG1 but low IL-
7R levels, characteristic of terminally-differentiated effectors (Fig 2.1c), with early 
effector cells (Obar et al., 2011) (EECs, KLRG1 oIL-7R o) and MPECs each 
comprising ~20% of TB10 tetramer+CD8+ T cells. Eight weeks later, TB10-specific 
CD8+ T cells are predominantly IL-7Rh  and ~50% express CD62L (Fig 2.1c). The 
majority of the TB10-specific CD8+ T cells express CXCR3, a chemokine receptor 
associated with CD27/CD70-dependent clonal expansion during priming 
(Peperzak et al., 2013), as well as trafficking of memory T cells to the airway during 
inflammation (Slütter et al., 2013) (Fig 2.1c). Thus, the TB10 / aCD40 / poly(I:C) 
vaccination strategy elicits large numbers of TB10-specific central memory and 
effector memory CD8+ T cells.  
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Figure 2.1: TB10 vaccination elicits memory CD8+ T cells that generate 2o effectors 
during Mtb infection. (a) The TB10 tetramer+ response enumerated by duel-tetramer 
staining in blood 1 week post-boost with TB104-11 or Ova257-264 (control) vaccination. 
Numbers indicate the % of CD8+ T cells. (b) TB10 tetramer+ responses from blood after 
TB104-11 or control (B8R20-27 or Ova257-264) vaccination at time points post-boost. (c) 
Representative plots showing CD62L, KLRG1, IL-7R, and CXCR3 expression by TB10 
tetramer+ CD8+ T cells from blood 1w after prime, and 1w or 8w after boost. (d) Ex vivo 
TB104-11-stimulated production of IFNg, TNF, or granzyme B from CD8+ T cells isolated 
from combined lungs, spleens, or LNs of TB10-vaccinated mice. (e) In vivo specific killing 
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of targets coated with TB104-11 peptide. (f) In vivo specific killing of 1μM TB104-11-coated 
targets vs. TB10-specific response. (g) TB10 tetramer responses of mice vaccinated with 
TB104-11 or the control peptide B8R20-27 immediately prior, or 2w, 4w, or 12w after Mtb 
infection.  **** p < 0.0001, *** p < 0.001, by two-way ANOVA with Sidak’s post test. Data 
are representative of 3-6 independent experiments, each with 4-6 mice per group.  
 
Vaccination with peptide / aCD40 / poly(I:C) elicited TB10-specific memory 
CD8+ T cells that secrete IFNg and TNF after ex vivo restimulation with the TB10 
peptide, or express granzyme B (Fig 2.1d). Vaccine-elicited TB10-specific CD8+ T 
cells also efficiently lysed peptide-loaded targets in vivo in a dose-dependent 
manner (Fig 2.1e, f). These data show that the effector functions expressed by 
vaccine-elicited CD8+ T cells are similar to those possessed by CD8+ T cells 
elicited by Mtb infection (Kamath et al., 2006). To determine the function of these 
memory T cells during infection, we vaccinated with TB10 or an irrelevant peptide 
(B8R20 27 from vaccinia (Baur et al., 2010)) and eight weeks after the boost, 
challenged the mice with Mtb. A discrete population of TB10-specific CD8+ T cells 
was detected in the lungs of the TB10 vaccinated mice even before infection (Fig 
2.1g). Two weeks after Mtb challenge, TB10-specific CD8+ T cells were more 
abundant in the lungs of TB10-vaccinated mice compared to the B8R-vaccinated 
group, although there was no difference in the number of tetramer+ CD8+ T cells 
between the two groups by four weeks (Fig 2.1g). Thus, by the peak of adaptive 
immunity in C57BL/6 mice (4 wpi), there was no difference in the number of TB10-
specific CD8+ T cells in the lungs of vaccinated and control-vaccinated mice, 
despite the effectiveness of vaccination with TB10 / CD40 / poly(I:C) in eliciting 
numerous functional memory CD8+ T cells.  
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Although vaccine-elicited TB10-specific CD8+ T cells were potent effectors 
and expanded early during infection, no differences were detected in the bacterial 
burden of vaccinated versus control mice (Fig 2.2a). We next sought to determine 
whether the lack of protection was related to insufficient numbers of memory CD8+ 
T cells prior to infection. As lipophilic vaccine adjuvants increase antigenicity (Liu 
et al., 2014), we modified the TB10 epitope by adding the hydrophobic amino acid 
residues ‘MFVMFVQ’ to the N-terminus of the minimal epitope of TB10. Eight 
weeks after priming and boosting with this amphiphilic peptide, denoted here as 
amphi-TB10, a greater proportion (20-45%) of circulating CD8+ T cells were 
specific for TB10, the majority of which were MPECs (Fig 2.2b). Despite a more 
robust response, neither prime-only nor prime-boost vaccination with amphi-TB10 
increased antigen-specific CD8+ T cell frequency or attenuated bacterial growth 
compared to sham-vaccinated mice by 4wpi (Fig 2.2c, d).   
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Figure 2.2: Vaccination with TB10.44-11 does not protect mice against Mtb infection.  
(a) Lung CFU 14d and 28d after Mtb infection of TB104-11 vaccinated, control vaccinated 
(B8R20-27 or Ova257-264), or unvaccinated mice. (b) Peripheral blood TB10 tetramer+ 
responses 8w post-prime or 8w post-boost with amphi-TB10 vaccination. CD62L, KLRG1, 
and IL-7R expression by tetramer+ CD8+ T cells is shown for each time point. (c) Lung 
CFU 28d after Mtb infection of amphiphilic-TB104-11 (amphi-TB10) or B8R20-27 vaccinated 
mice. Bacterial counts were log10-transformed and compared using a student’s t-test or 
one-way ANOVA. (d) Lung tetramer+ responses from amphi-TB10 prime/boost-vaccinated 
(3 weeks apart), negative control-vaccinated (B8R), or unvaccinated mice 28d after Mtb 
infection. n.s., not significant. Data are representative of 3 - 6 independent experiments, 
each with 4 - 6 mice per group. 
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 Finally, to determine whether the progressive decrease in abundance of 
memory CD8+ T cells during TB, or their inability to control bacterial CFU, are 
related only to those specific for the TB10.4 antigen, we evaluated the response of a 
second Mtb antigen. The H2-Db-restricted epitope GAPINSATAM (Mtb32A309-319) (Irwin et 
al., 2005), referred to hereafter as Mtb32a, is known to elicit CD8+ T cells after aerosol 
Mtb infection. Therefore, mice were vaccinated using Mtb32a peptide together with 
aCD40 mAb and poly(I:C), which generated a robust response 1 week after boost (Fig 
2.3a, left panel) and contracted to a smaller cohort of memory T cells by 8 weeks (Fig 
2.3a, right panel), at which point they were aerosol-infected with Mtb. Four weeks after 
Mtb aerosol challenge, the numbers of Mtb32 tetramer+ CD8+ T cells in vaccinated and 
unvaccinated mice were again the same (Fig2.3b), and no difference in bacterial growth 
in the lungs was observed (Fig 2.3c). Thus, despite being highly functional, as 
measured by their expression of IFNg, TNF, and granzyme B after stimulation, their 
CTL activity, their abundance 8-12 weeks after the boost, and their response to 
Mtb aerosol challenge, memory CD8+ T cells elicited by peptide / aCD40 mAb / 
poly (I:C) vaccination are unable to maintain their abundance or control bacterial 
CFU in intact mice after aerosol Mtb infection. Together, these data raise the 
possibility that the inability of 2° effector CD8+ T cells to predominate in response 
to Mtb is related to a failure of memory CD8+ T cells to optimally expand rather 
than insufficient numbers prior to infection.  
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Figure 2.3: Vaccination against a the Mtb32a antigen does not lead to protection or 
a greater frequency of memory-derived T cells. (a) Representative flow cytometry plots 
of the proportion of TB10 tetramer+ CD8+ T cells (gated on CD8+) from the blood of mice 
1 week (left panel) or 8 weeks (right panel) after prime / boost vaccination. (b) Bar graphs 
of the proportion of Mtb32a-specific CD8+ T cells (mean ± SEM) in the lungs of Mtb32a-
vaccinated vs. unvaccinated mice 4 weeks post aerosol Mtb infection (left), or 18 weeks 
post-infection (right panel). (c) Lung CFU (mean ± SEM) in Mtb32a-vaccinated vs. 
unvaccinated mice 4 weeks post-infection. *** p < 0.001, n.s. not significant by the 
student’s t-test. Data are representative of 3 independent experiments, each with 4-7 mice 
per group. 
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Direct comparison of memory and naïve T cells using TCR retrogenic TB10-
specific CD8+ T cells 
To directly compare how memory and naïve TB10-specific CD8+ T cells 
behave during Mtb challenge, we used TCR retrogenic (Rg) mice producing CD8+ 
T cells specific for TB10 (TB10Rg3) (Nunes-Alves et al., 2015). Vaccination 
increased the frequency of TB10Rg3 CD8+ T cells (GFP+Va2+), and 60-70% of 
expressed CD44 compared with ≤5% in unvaccinated mice (Fig 2.4a). After 8 
weeks, TB10Rg3 cells contracted into a uniform population of central memory T 
cells (CD62Lh IL-7Rh ) (Fig 2.4b). 
We previously found that the adoptive transfer of activated TB10Rg3 CD8+ 
T cells reduced bacterial CFU and prolonged the survival of susceptible mice 
(Nunes-Alves et al., 2015). Here we compared the protective capacity of flow-
sorted naïve (GFP+Va2+CD44 o cells) or memory (GFP+Va2+CD44H ) TB10Rg3 
CD8+ T cells by transferring 105 of each into TCRa /  mice and challenging with 
Mtb. Both naïve and memory TB10Rg3 CD8+ T cells expanded and differentiated 
into terminally-differentiated effectors (KLRG1H IL-7R o) and EECs (KLRG1LoIL-
7R o), with a small population of MPECs (KLRG1LoIL7RH ), and produced IFNγ after 
restimulation in vitro (Fig 2.4c, d). Naïve, effector, and memory TB10Rg3 CD8+ T 
cells transferred protection to immunodeficient mice (Fig 2.4e, f), indicating that 
these cells have the potential to independently function as effector T cells and 
attenuate infection.   
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Figure 2.4: TCR retrogenic TB10-specific CD8+ T cells allow direct comparison of 
the 1o and 2o responses during infection. (a) The proportion of TB10Rg3 cells 
(%GFP+Va2+) among CD8+ T cells and their CD44 expression, 8w after vaccination of 
TCR Rg mice (memory) or age-matched unvaccinated TCR Rg mice (naïve). (b) CD62L, 
KLRG1, and IL-7R expression of naïve TB10Rg3 cells, and 8w after a single immunization 
with TB104-11. (c) Proportion (left) and absolute numbers (right) (mean ± SEM) of TB10Rg3 
cells in the lungs of TCRa-/- mice 28d after adoptive transfer of 105 naïve or memory 
TB10Rg3 CD8+ T cells and Mtb infection. (d) Ex vivo KLRG1 and IL-7R expression by 
TB10Rg3 cells (left) and IFNg production after ex vivo stimulation of lung cells [from (c)] 
with TB104-11 peptide (right). (e) Lung CFU (mean ± SEM) of TCRa-/- mice 28d after 
transfer of naïve or memory TB10Rg3 CD8+ T cells and Mtb infection. (f) Lung CFU of 
sub-lethally irradiated C57BL/6 mice 21d after Mtb infection and transfer of memory 
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TB10Rg3 (8w post-vaccination; left) or effector TB10Rg3 (1w post-vaccination; right). 
Numbers in quadrants or gated regions represent percent events. CFU were log10-
transformed before a student’s t-test or one-way ANOVA with a Bonferroni post-test. Data 
are representative of 2–4 independent experiments, each with 5 mice per group. * p < 
0.05. n.s., not significant. 
 
Although memory TB10Rg3 CD8+ T cells expanded, differentiated, and 
attenuated bacterial growth after adoptive transfer, the inability to distinguish the 
memory-recall response in intact vaccinated mice from the primary response in 
unvaccinated mice by 4wpi (Fig 2.1g), as well as the inability of TB10 vaccination 
to confer additional protection to the endogenous primary  immune response 
(Lindenstrøm et al., 2014) (S1 Fig), led us to hypothesize that memory CD8+ T 
cells were not optimally responding in vivo. In our comparison of TB10-specific 
CD8+ T cell responses of vaccinated and unvaccinated mice, the primary response 
(e.g., in unvaccinated mice) appears to undergo more rapid expansion than the 
recall response (e.g., in vaccinated mice) (Fig 2.1g). Therefore, we developed an 
adoptive co-transfer model to study the 1° and 2° effector responses generated 
from naïve and memory TB10Rg3 CD8+ T cells, respectively, during Mtb 
challenge. 
 
Primary effectors progressively outnumber secondary effector CD8+ T cells 
during Mtb infection 
Thy1.1+ memory and Thy1.2+ naïve TB10Rg3 CD8+ T cells were transferred 
(1:1 ratio, 104 cells each) into CD45.1+ recipient mice infected with Mtb seven days 
earlier, before the onset of adaptive immunity (Fig 2.5a,b). Nearly all (>80%) of the 
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memory TB10Rg3 CD8+ T cells had a central memory phenotype 
(CD62Lh KLRG1 oIL-7Rh ), suggestive of a high proliferative potential (Fig 2.5b). As 
a control, the memory and naïve TB10Rg3 CD8+ T cells were adoptively 
transferred into uninfected or Mtb-infected mice and analyzed the next day. 
Analysis of these cells showed that they maintained their phenotype, 1:1 ratio, and 
based on results with the eFluor450 proliferation dye, neither group had begun to 
proliferate (Fig 2.5c).  
While naïve T cells require priming in the lung-draining mediastinal lymph 
nodes (MLN) before responding to infection in the lung (Wolf et al., 2008), whether 
memory T cell activation occurs in the MLN or lung is unknown. By loading naïve 
and memory TB10Rg3 CD8+ T cells with eFluor450, we determined that both 
memory and naïve TB10Rg3 CD8+ T cells begin to proliferate and downregulate 
CD62L first in the MLN by d11 post-infection (Fig 2.5d), during which time they 
maintain their 1:1 ratio despite significant proliferation (see below). This timing 
correlates with priming of the endogenous CD8+ T cell response to TB10 (Nunes-
Alves et al., 2015).  
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Figure 2.5: The primary response outnumbers the memory-derived secondary 
response during Mtb infection. (a) Experimental strategy for adoptive co-transfer 
experiments. Relative proportion of naïve and memory TB10Rg3 CD8+ T cells and their 
expression of CD62L, KLRG1, and IL-7R before transfer (b) and in the spleen 1d after 
transfer into uninfected mice (c). Baseline labeling with the eFluor450 proliferation dye is 
shown. (d) Concatenated histograms of eFluor450 staining of naïve and memory-derived 
TB10Rg3 cells in the MLN, lung, and spleen (top) and their CD62L and CD44 expression 
(bottom) from a representative experiment on d11 post-infection. (e) Proportion of 
adoptively-transferred memory (Thy1.1+) and naïve (Thy1.2+)-derived TB10Rg3 CD8+ T 
cells in the lung 15, 18, or 21d after Mtb infection. (f) The relative proportion of memory 
(Thy1.1) and naïve (Thy1.2)-derived TB10Rg3 CD8+ T cells in the MLN, lung, and spleen 
after infection, compared to spleens from uninfected mice 1 day after transfer (CTRL) 
(top). Cell numbers of memory (Thy1.1+) and naïve (Thy1.2+)-derived TB10Rg3 CD8+ T 
cells from the same mice (bottom). **** p < 0.0001, n.s. not significant, n.d. < 10 cells 
detected. Data are representative of 2–10 independent experiments, each with 3–4 mice 
per group. 
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Following activation in the MLN, massive expansion of naïve and memory 
TB10Rg3 CD8+ T cells occurs in the MLN, lung and spleen through day 15, still 
maintaining an equal ratio (Fig 2.5e,f). After day 15, the 1o effectors (derived from 
naïve T cells) become dominant in all three tissues, and by day 21, the 1o effectors 
outnumber the 2° effectors (derived from memory T cells) by a ratio of 99:1 in the 
lung (Fig 2.5e,f). The accumulation of the 1o effectors is driven by their ongoing 
proliferation and dropout of 2° effector cells, particularly in the lung (Fig 2.5f, 
bottom row). Thus, the 1o CD8+ T cell response expands more efficiently than the 
2° response during Mtb challenge. 
To determine whether the observed phenomenon of memory TB10Rg3 
CD8+ T cells becoming outnumbered by naïve TB10Rg3 cells during TB was 
specific to the method of generating memory, we compared two other vaccination 
strategies. In the previous experiments, we generated memory CD8+ T cells by 
direct vaccination of intact TB10Rg3 mice containing a low frequency of TB10Rg3 
cells due to the concern that adoptively transferring low numbers of T cells followed 
by stimulation by vaccination would impair their function (Fraser et al., 2013). 
However, to evaluate the function of memory TB10Rg3 cells generated by a 
standard approach, we used the “transfer-then-vaccinate” strategy. One day after 
transferring 1x104 naïve CD45.1+ TB10Rg3 CD8+ T cells, recipient mice were 
vaccinated with TB10 / aCD40 / Poly (I:C), rested for 12 weeks, and the memory 
TB10Rg3 CD8+ T cells were flow-sorted (CD8+ Va2+ GFP+ CD45.1+ KLRG1Lo 
CD44h ) and adoptively co-transferred (together with CD45.2+ naïve TB10Rg3 
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cells) into Thy1.1+ hosts 6d after aerosol infection with Mtb as in Fig 2.5a. Memory 
and naïve TB10Rg3 CD8+ T cells were injected at a ~1:1 ratio, however by d22 
the naïve CD8+ T cells outnumbered memory CD8+ T cells >90:1 (Fig 2.6a). Thus, 
memory CD8+ T cells specific for TB10.4 become outnumbered even when 
generated using the standard transfer-then-vaccinate approach. Finally, to 
determine whether memory CD8+ T cells generated by a different vaccination 
strategy suffer the same fate, we adoptively transferred 1x104 naïve CD45.1+ 
TB10Rg3 CD8+ T cells and, one day later, vaccinated recipient mice with 
recombinant Listeria monocytogenes engineered to secrete a fusion protein 
containing full-length TB10.4 (LmΔActA-TB10) (Curtis et al., 2010; Shafiani et al., 
2013). 12 weeks later, memory TB10Rg3 CD8+ T cells were again flow-sorted and 
adoptively co-transferred (1:1 with CD45.2+ naïve TB10Rg3 cells) into Thy1.1+ 
hosts 6d after aerosol infection with Mtb. 22 days post-infection, the naïve CD8+ T 
cells again outnumbered memory CD8+ T cells >95:1 (Fig 2.6b). Thus, the 
observed phenomenon of naïve CD8+ T cells outnumbering memory CD8+ T cells 
specific for TB10.4 during TB occurs with memory T cells generated by other 
vaccine strategies.   
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Figure 2.6: Memory TB10Rg3 CD8+ T cells generated by alternative methods also 
become outnumbered by naïve CD8+ T cells during Mtb infection. Bar graphs (Left) 
and flow cytometry plots (right) of the relative proportion of memory (CD45.1) and naïve 
(CD45.2)-derived TB10Rg3 CD8+ T cells (mean ± SEM) in the lung 22d after infection 
(D22 Lung), compared to spleens from uninfected mice 1 day after transfer (D7 Ctrl) for 
each strategy: (a) Memory TB10Rg3 CD8+ T cells were generated by adoptive transfer of 
104 naïve TB10Rg3 cells followed by vaccination with TB10 / aCD40 mAb / Poly(I:C) one 
day later, rested for 12 weeks, followed by co-transfer with naïve TB10Rg3 into Mtb-
infected hosts. (b) Memory TB10Rg3 CD8+ T cells generated by adoptive transfer of 104 
naïve TB10Rg3 cells followed by vaccination with LmΔActA-TB10 one day later, rested 
for 12 weeks, followed by co-transfer with naïve TB10Rg3 into Mtb-infected hosts. **** p 
< 0.0001, n.s. not significant. Data are representative of 2 independent experiments, each 
with 4 mice per group. 
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Sustained proliferation of primary effectors during infection leads to their 
dominance 
Joshi et al. find that during infection, a subset of effector CD8+ T cells 
differentiate into cells that can no longer proliferate in response to antigen and 
express the inhibitory receptor KLRG1, now identified as a marker of terminal 
differentiation (Joshi et al., 2007). We examined whether the attrition of the 
secondary effectors correlated with terminal differentiation. Both 1° and 2° effector 
CD8+ T cells were predominantly EECs (KLRG1Lo IL-7RLo) at all time points (day 
15-21), with slightly more terminally-differentiated effectors (KLRG1H  IL-7RLo) in 1o 
effectors, rather than in 2° effectors (Fig 2.7a), arguing against terminal 
differentiation as an explanation for their observed decreased rate of expansion. 
The attrition of secondary effector CD8+ T cells during infection is also independent 
of TCR affinity, since TCR retrogenic TB10Rg3 cells were the source of both the 
naïve and memory precursors. Furthermore, we found TCR expression to be 
equivalent between both memory and naïve-derived TB10Rg3 cells during 
infection (Fig 2.7b). Finally, since Mtb-specific T cells can differ in their ability to 
traffic to the lung (Moguche et al., 2015; Sakai et al., 2014a), we considered 
whether naïve and memory-derived TB10Rg3 cells might differentially home to the 
lung. Equal proportions of 1o and 2o effector CD8+ T cells were found in the 
“intravascular” or “parenchymal” compartments, as defined by intravenous 
administration of anti-Va2 mAb (Fig2.7c). Thus, the 1o and 2o effector CD8+ T cell 
responses were able to traffic similarly to the lungs of Mtb-infected hosts. 
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Interestingly, we found the cohort of CD8+ T cells (from both groups) to have a 
higher “intravascular” proportion at the early time point (d14), compared with later 
time points (d18, d21) (Fig 2.7c). Sakai et al. show that “intravascular” T cells 
exhibit more terminal differentiation, a decreased ability to control Mtb growth, and 
are less likely to traffick to the lung parenchyma after adoptive transfer into Mtb-
infected hosts. (Sakai et al., 2014a). Therefore, the sequential increase in 
proportion of “parenchymal” CD8+ T cells specific for TB10.4 (and decrease in 
“intravascular” T cells) as infection progresses implies appropriate trafficking, and 
the potential for both the 1o (naïve-derived) and 2o (memory-derived) TB10.4-
specific CD8+ T cell responses to control Mtb growth in the lungs. 
Next, we determined whether 1° and 2° effector CD8+ T cells proliferate 
differently during infection. On d18 post-infection, 1o effector TB10Rg3 CD8+ T 
cells had ~40% more EdU uptake than 2° effectors (Fig 2.7d). In contrast, no 
differences in the frequency of apoptotic cells, measured using an activated 
caspase-3 antibody or with a viability dye, were detected (Fig 2.7e). These data 
suggest 2o effectors become outnumbered due to a decreased rate of 2° effector 
CD8+ T cell proliferation after d15, while a greater rate of 1o effector proliferation 
leads to continued exponential expansion.  
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Figure 2.7: Increased proliferation accounts for differences in 1o and 2o TB10Rg3 
CD8+ T cell abundance during TB. (a) KLRG1 and IL-7Ra expression by memory and 
naïve-derived TB10Rg3 cells recovered from lung at each time point. (b) TCR Va2 median 
fluorescence intensity (MFI) (median ± SEM) in memory and naïve-derived TB10Rg3 
CD8+ T cells from the same mice at d15 and d18 post-infection. (c) Proportion (mean ± 
SEM) of memory or naïve-serived TB10Rg3 cells in lung homogenate that stained with 
anti-TCR Va2 mAb that was injected i.v. immediately prior to euthanasia as well as anti-
TCR Vb11 staining of the lung homogenate (i.v.+ “intravascular”), vs. those that only 
stained with anti-TCR Vb11 (i.v.-, “parenchymal”) at d14, d18, and d21 post-infection. (d) 
EdU uptake (mean ± SEM) by memory and naïve-derived TB10Rg3 cells recovered from 
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lung. (e) Bar graphs of the frequency of activated caspase-3 expression and viability dye 
(Zombie Aqua, Biolegend) expression on TB10Rg3 cells derived from naïve (1o) and 
memory (2o) precursors in the lungs of Mtb-infected mice 15d post aerosol Mtb challenge. 
* p<0.05, n.s. not significant. Data are representative of 3 independent experiments, each 
with 3-4 mice per group. 
 
Memory CD8+ T cells have a higher activation threshold than naïve CD8+ T 
cells 
To determine whether the observed reduced proliferation was an intrinsic 
property of memory CD8+ T cells, or was precipitated by extrinsic signals in the 
inflammatory environment of the infected lung, we studied T cell expansion in a 
model of acute infection and two non-infectious models. First, naïve and memory 
TB10Rg3 CD8+ T cells were co-transferred into mice challenged with amphi-TB10 
peptide together with anti-CD40 mAb and poly(I:C) one day earlier. One week after 
transfer into amphi-TB10 challenged mice, significant expansion had occurred in 
both groups but the ratio of 1° and 2° effectors remained ~1:1, with a predominance 
of 2° effectors late during expansion (Fig 2.8a). One day after 1:1 co-transfer of 
memory and naïve TB10Rg3 CD8+ T cells, mice were also challenged 
intravenously with the recombinant Listeria monocytogenes strain engineered to 
secrete TB10.4 (LmΔActA-TB10). Four days after LmΔActA-TB10 challenge, 
during a period of robust expansion, both groups expanded equally to TB10.4 
antigen. During the contraction of the response (d7), the TB10Rg3 CD8+ T cells 
derived from memory were more abundant than those derived from naïve 
TB10Rg3 CD8+ T cells resulting in an 80:20 ratio favoring the 2o effectors (Fig 
2.8b). Finally, homeostatic proliferation of naïve and memory TB10Rg3 CD8+ T 
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cells was also measured three weeks after their transfer into TCRa /  mice, and the 
dividing cells also maintained an equal ratio (Fig 2.8c). Thus, 2o effector CD8+ T 
cells have the potential to proliferate as well as 1o effectors during acute infection 
or after non-infectious antigenic stimuli.   
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Figure 2.8: Memory and naïve CD8+ T cells both exhibit strong proliferation potential 
(a) The proportions of naïve and memory-derived TB10Rg3 cells in the lung (left) or spleen 
(right) 1, 7, or 50 d after adoptive co-transfer into mice administered amphi-
TB10/poly(I:C)/CD40 1d prior to transfer (mean ± SEM). (b) Bar graphs (left) and 
representative flow plots (right) of the proportion of splenic TB10Rg3 CD8+ T cells (mean 
± SEM) derived from memory (CD45.1+) or naïve (CD45.2+) TB10Rg3 0, 4, or 7 days after 
i.v. LmDActA-TB10 challenge of Thy1.1+ hosts, in which 104 memory and naïve TB10Rg3 
cells were co-transferred at a 1:1 ratio 1 day prior to challenge. (c) Histogram of 
proportions of memory (red) and naïve (blue) TB10Rg3 cells that have diluted proliferation 
dye eFluor450, recovered from the spleens 21d after adoptive-co-transfer into TCRa-/- 
mice.  Bar graph comparing the ratios of naïve and memory TB10Rg3 cells (mean ± SEM) 
among those undergoing >1 division during homeostatic proliferation. Ratios were 
compared using student’s t-tests. * p < 0.05, ** p < 0.01, **** p < 0.0001, n.s. not significant. 
Data are representative of 2-3 independent experiments, each with 3-4 mice per time 
point. 
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Mehlhop-Williams and Bevan find that memory CD8+ T cells require more 
antigen for activation than naïve CD8+ T cells, which results in less proliferation of 
secondary effectors when antigen is limiting (Mehlhop-Williams and Bevan, 2014). 
Both the antigen-challenge and the listeria models are scenarios in which TB10.44
11 is likely to be present in abundance. To formally determine whether the 
proliferation of memory TB10Rg3 CD8+ T cells is affected by antigen availability, 
mice were challenged with amphi-TB10/aCD40/poly(I:C) i.v. 1d or 21d prior to co-
transfer of naïve and memory TB10Rg3 CD8+ T cells to simulate high or low 
antigen conditions, respectively. Both naïve and memory CD8+ T cells proliferated 
similarly 3d after exposure to high antigen conditions (Fig 2.9a, b). However, 1o 
effectors underwent more cell divisions than 2° effectors when exposed to low 
antigen conditions (Fig 2.9c), and increased in number relative to the 2° effectors. 
Finally, naïve and memory TB10Rg3 CD8+ T cells differed in their sensitivity to 
peptide concentration in vitro. Memory T cells required 32-fold more peptide to 
trigger proliferation than naive T cells (Fig 2.9c). Thus, a low antigen environment 
recapitulates the bias towards primary effectors that we identified during Mtb 
infection. 
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Figure 2.9: Memory CD8+ T cells have a higher activation threshold than naïve CD8+ 
T cells. (a, b) The proportion of splenic TB10Rg3 cells (mean ± SEM) derived from naïve 
or memory TB10Rg3 3d after their co-transfer into mice administered amphi-
TB10/poly(I:C)/CD40 1d (high antigen) or 21d (low antigen) prior to transfer. Bar graphs 
of their ratios (a) and dilution of proliferation dye (b) are shown. (c) eFluor450 dilution by 
naïve or memory TB10Rg3 cells 64h after culture with peptide-coated splenocytes (left) 
and summary of dose-response data (right). **** p < 0.0001, n.s. not significant. Data are 
representative of 2 independent experiments, each with 3-4 mice per group. 
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Higher TCR affinity offsets memory CD8+ T cell loss during tuberculosis. 
Since greater amounts of peptide-MHC complexes (pMHC) are required to 
trigger memory CD8+ T cell entry into the cell cycle (Mehlhop-Williams and Bevan, 
2014) (Fig 2.9), we sought to determine whether TCR affinity modulated the fitness 
of memory CD8+ T cells during the response to Mtb challenge. We recently 
generated TCR retrogenic mice with TB10-specific CD8+ T cells that contain a TCR 
with a higher-affinity for TB10.44 11 (TB10Rg4, TCR4), in addition to mice 
containing the intermediate-affinity TCR (TB10Rg3, TCR3) (Fig 2.10) (Nunes-
Alves et al., 2015). The increased affinity of TCR4 in naïve TB10Rg4 cells was 
determined in naïve TB10-specific CD8+ T cells by tetramer staining using limiting 
dilutions of tetramer (Fig 2.10a). Furthermore, the relative expansion and 
abundance of TB10Rg4 vs. TB10Rg3 CD8+ T cells was measured in lung and 
draining lymph nodes during priming of the adaptive immune response after 
aerosol infection with Mtb (Fig 2.10 b,c), exhibiting the preferential expansion of 
antigen-specific T cells with the higher TCR affinity.   
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Figure 2.10: Differences in TCR affinity can lead to clonotypic dominance during 
infection.  (a) Flow-cytometry analysis of affinity of TB10Rg3 (TCR3, open circles) and 
TB10Rg4 (TCR4, filled circles) CD8+ T cells from uninfected TCR retrogenic mice. Affinity 
is based on the frequency of tetramer staining of Rg cells across multiple tetramer 
concentrations. (b, c) Kinetic analysis of frequency (b) and number (c) of TB10Rg3 (open 
symbols) or TB10Rg4 (filled symbols) CD8+ T cells in the draining LN (left panels) and 
lung (right panels) following adoptive co-transfer into mice infected with M. tuberculosis 
(mean ± SEM). Data are representative from two (b, c) or three (a) independent 
experiments, each with 5 mice per group. (b, c) Two way ANOVA with Holm-Sidak’s 
multiple comparison test; ** p < 0.01, *** p < 0.001, **** p < 0.0001). 
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Using these TCR retrogenic mice, we vaccinated mice containing 
congenically-marked TB10Rg4 CD8+ T cells and rested age-matched, naive 
TB10Rg4 mice for an equivalent period of time (8-12 weeks) to compare the 
expansions of higher-affinity memory CD8+ T cells with their naïve counterparts. 
To determine whether the affinity of the TCR affects the relative ability of memory 
and naïve CD8+ T cells to expand, we co-transferred memory and naïve TB10Rg4 
CD8+ T cells at a 1:1 ratio into Mtb-infected mice. Using the same methodology 
(Fig 2.5a), we tracked the relative expansions of 1° and 2° effector CD8+ T cells. 
Similar to our previous results, the TB10Rg4 naïve CD8+ T cells expanded more 
than TB10Rg4 memory CD8+ T cells (Fig 2.11a). Although those derived from 
TB10Rg4 memory were again outnumbered by d21 post-infection, the effect was 
less extreme, resulting in a ratio of ~4:1 favoring the 1o effector CD8+ T cells in 
MLN, lung, and spleen (Fig 2.11a). Differences in the expansion of memory and 
naïve TB10Rg4 CD8+ T cells were again independent of surface TCR levels as 
TCR Va2 MFI were equivalent (Fig 2.12). Thus, for a second TB10.44 11–specific 
TCR, we see a similar predilection for the 1° effectors to outnumber the 2° effector 
CD8+ T cells. Although these higher-affinity memory CD8+ T cells did not begin 
responding to Mtb earlier than the lower affinity (TB10Rg3) memory response, they 
displayed improved fitness.  
Finally, we sought to determine whether higher affinity memory T cells were 
more fit than lower affinity naïve T cells. Memory TB10Rg4 and naive TB10Rg3 
CD8+ T cells were co-transferred at a 1:1 ratio into mice infected 6-7 days earlier, 
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and their expansion and ratio tracked through d21 post-infection. Memory 
TB10Rg4 CD8+ T cells successfully competed, significantly outnumbering naïve-
derived TB10Rg3 CD8+ T cells by d14 post-infection in MLN, lung, and spleen (Fig 
2.11b). By d21, the 2° TB10Rg4 effectors dominated the 1o TB10Rg3 effectors by 
a ratio of 50:1. Although memory CD8+ T cells have a higher antigen threshold for 
their activation, a higher TCR affinity for pMHC helps memory-derived CD8+ T cells 
to compete with those derived from naïve CD8+ T cells during tuberculosis. We 
infer that affinity plays an important role in the success of memory-derived effector 
CD8+ T cells during TB. 
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Figure 2.11: Memory CD8+ T cells with a higher affinity TCR can display improved 
responses during tuberculosis. (a) Proportion (mean ± SEM) of adoptively-transferred 
memory (CD45.1+) and naïve (CD45.2+)-derived TB10Rg4 CD8+ T cells in the MLN, lung, 
and spleen 14, 18, or 21d after Mtb infection, compared to spleens from uninfected mice 
1 day after adoptive transfer (CTRL) (top). Cell numbers of memory and naïve-derived 
TB10Rg4 CD8+ T cells from the same mice (bottom). (b) The relative proportion (mean ± 
SEM) of adoptively-transferred, memory-derived TB10Rg4 (Vb5+) and naïve-derived 
TB10Rg3 (Vb11+) CD8+ T cells in the MLN, lung, and spleen 14, 18, or 21d after Mtb 
infection, compared to those in the spleens of uninfected mice 1 day after adoptive transfer 
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(CTRL) (top). Cell numbers of memory-derived (TB10Rg4) and naïve-derived (TB10Rg3) 
CD8+ T cells from the same mice at each time point during infection (bottom). * p < 0.05, 
** p < 0.01, *** p < 0.001, **** p < 0.0001, n.s. not significant. Data are representative of 2 
independent experiments, each with 4 mice per group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12: 1o and 2o TB10Rg4 CD8+ T cells contain equal TCR expression. Bar 
graphs of median fluorescence intensity (MFI) of TCR Va2 expression on TB10Rg4 cells 
derived from naïve (1o) and memory (2o) precursors in the lungs of Mtb-infected mice 14, 
18, and 21d post aerosol Mtb challenge. Va2 MFIs were compared using student’s t-tests. 
n.s. not significant. Data are representative of 2 independent experiments, each with 4 
mice per group (time point). 
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Discussion 
In this study, we discovered unexpected limitations in the expansion of 
memory-derived CD8+ T cells specific for an immunodominant Mtb antigen, 
providing one explanation for why T cell vaccines may be ineffective in preventing 
TB. By directly comparing naïve and memory CD8+ T cells using our adoptive co-
transfer model, we show that both memory and naïve T cell responses are initiated 
in the MLN with similar kinetics. Thus, both primary and secondary responses are 
subject to significant delay before T cell expansion and recruitment to the lung 
occurs following Mtb challenge. Furthermore, once T cells traffic to the lungs, 2° 
effectors derived from memory precursors become rapidly outnumbered as their 
expansion plateaus after d15 post-infection, making them difficult to detect by d21. 
While this effect is modulated by TCR affinity, these kinetics may explain why the 
superiority of natural memory T cell responses are limited to a narrow window early 
after infection (Jung et al., 2005; Kamath and Behar, 2005). Furthermore, the 
phenotype of the memory T cells we generated by vaccination is that of central 
memory (CD62LH  IL-7RH ). As central memory T cells reside mostly in the draining 
lymph nodes, it may not be surprising that their activation occurs in the MLN and 
requires trafficking of antigen and/or antigen-laden APCs. Although central 
memory T cells are speculated to have superior proliferative capacity and mediate 
robust protection in adoptive transfer models (Sallusto et al., 1999), the 
requirement for priming in the LN could delay their response to Mtb, hindering the 
oft-cited benefit of a memory response: rapid recall. 
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The data presented here indicate that an important characteristic of memory 
T cells responding to Mtb is their ability to respond to antigen present in low-
abundance and proliferate rapidly. We argue that the efficiency of memory T cell 
proliferation after exposure to low amounts of antigen can be tested during vaccine 
development as a benchmark for viable TB vaccine candidates. Although 
sensitivity to low antigen is not the only characteristic sufficient for a successful TB 
vaccine, it is likely a necessary component. The ability of a TB vaccine candidate 
to generate memory T cells that respond to limiting amounts of antigen in the lung 
soon after inoculation, and offer consistent control of bacterial growth in animal 
models, would represent a significant advance in TB prevention by vaccination. 
Such a vaccine candidate would be worthy of the rigor and expense of human 
clinical trials. 
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Materials and Methods 
Ethics Statement. The animal studies were approved by the Institutional Animal 
Care and Use Committee at the Dana Farber Cancer Institute or the University of 
Massachusetts Medical School (Animal Welfare Assurance no. A3023-01 [DFCI] 
or A3306-01 [UMMS]), using the recommendations from the Guide for the Care 
and Use of Laboratory Animals of the National Institutes of Health and the Office 
of Laboratory Animal Welfare.  
 
Mice. C57BL/6J (WT; CD45.2+Thy1.2+), CD45.1 (B6.SJL-PtprcaPepcb/BoyJ; 
CD45.1+Thy1.2+), CD90.1 (B6.PL-Thy1a/CyJ; CD45.2+Thy1.1+), TCRa KO 
(B6.129S2-Tcratm1Mom/J) mice were purchased from Jackson Laboratories (Bar 
Harbor, ME) and housed under specific pathogen-free conditions at Dana Farber 
Cancer Institute or University of Massachusetts Medical School animal facilities. 
Mice were 7 to 10 weeks old at the start of all experiments. Infected mice were 
housed in biosafety level 3 facilities under specific pathogen-free conditions at 
DFCI or UMMS.  
 
Generation of TCR retrogenic mice. TCR retroviral constructs were generated 
and retrogenic mice produced using protocols developed by the Vignali lab (Holst 
et al., 2006). Details of the TCRs, cloning strategies and primer sequences have 
been recently published (Nunes-Alves et al., 2015). Retroviral-mediated stem cell 
gene transfer was performed using bone marrow from CD45.2+Thy1.2+, 
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CD45.1+Thy1.2+, or CD45.2+Thy1.1+ mice, which was transferred into C57BL/6 
recipients that were lethally-irradiated one day earlier with a split dose of 1200 
Rads administered using a GammaCell 40 Cs137 Irradiator (Theratronics, Ottawa, 
ON, Canada). Reconstitution was measured 6 weeks later. 
 
Vaccination and assessment of immune responses. TB10.44 11 (IMYNYPAM), 
B8R20 27 (TSYKFESV), “amphi-TB10” (MFVMFVQIMYNYPAM), and ovalbumin257
264 (SIINFEKL) peptides were purchased from New England Peptides (Gardner, 
MA, USA) and reconstituted in DMSO (10mM). High molecular weight 
polyinosinic:polycytidylic acid [poly(I:C)] was obtained from InvivoGen (San Diego, 
CA). Anti-CD40 mAb (clone FGK4.5) was purchased from BioXCell (West 
Lebanon, NH). Vaccines were prepared by mixing 100 micromoles of peptide, 50 
µg poly(I:C), and 50 µg aCD40 mAb, in a total volume of 200 µL sterile PBS and 
administered intravenously. Where indicated, mice were boosted with the same 
vaccine 3 weeks later. In some experiments, peripheral blood T cell responses 
were monitored by flow cytometry. Mice were rested 8–12 weeks after the last 
vaccination to allow for the development of memory. Memory cells were generated 
using two different strategies. Since serial adoptive transfers of memory T cells 
can decrease their protective and proliferative capacities (Fraser et al., 2013), 
TB10Rg3 or TB10Rg4 mice having a low frequency of peripheral blood retrogenic 
cells (3-17%), were directly vaccinated with TB10/CD40/poly(I:C). In other 
experiments, 20,000 naïve TB10Rg3 CD8+ T cells were adoptively transferred into 
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C57BL/6 mice (resulting in 200 - 2,000 naïve precursor T cells after a 1-10% 
“take”). Those mice were then vaccinated as described above. In both cases, mice 
were rested for 8-12 weeks after vaccination to allow the development of memory. 
A comparison of memory TB10Rg3 CD8+ T cells elicited by vaccination after 
adoptive transfer of TB10Rg3 cells into B6 mice to those generated by vaccination 
of intact retrogenic mice showed similar results. Naïve TB10-specific CD8+ T cells 
were obtained from unvaccinated, age-matched TB10Rg3 or TB10Rg4 mice 
rested for an equivalent period of time. 
 
Experimental infection and bacterial quantification. Mtb (strain Erdman) 
infections were performed via the aerosol route as described previously 
(Chackerian et al., 2002). 1mL Mtb Erdman culture was thawed from a frozen stock 
of broth culture in Middlebrooke 7H9 medium frozen at -80oC at mid-log phase 
growth. The same frozen stock was used for all experiments. Mice received an 
inoculation dose of 100-150 CFU/mouse, as measured within 24 hours of infection. 
The inoculum was quantified in control mice 1 day after aeorosol inoculation by 
plating neat lung homogenate onto 7H11 agar plates. Infections at UMMS were 
performed using a Glas-Col full body inhalation exposure system (Terre Haute, 
IN). Mice received an inoculation dose of 30-190 CFU/mouse, as measured within 
24 hours of infection. At different times post-infection, mice were euthanized, 
organs were aseptically removed, individually homogenized, and viable bacteria 
were enumerated by plating 10-fold serial dilutions of organ homogenates onto 
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7H11 agar plates.  
Recombinant Listeria monocytogenes expressing the full-length TB10.4 
coding sequence (LmDActA-TB10) was generated by amplifying the full-length 
coding sequence of TB10.4 from Mtb genomic DNA and cloning into the gram 
positive expression vector pAM401 behind the promoter and signal sequence for 
Listeria monocytogenes hly encoding Listeriolysin-O. This construct was 
electroporated into attenuated DActA Listeria monocytogenes that retains access 
to the cytoplasmic compartment of infected cells as described previously for ESAT-
6 and Ag85b constructs (Curtis et al., 2010; Shafiani et al., 2013).  Bacteria 
containing the plasmid were grown to mid-log phase (OD600 0.4-0.8) in brain-heart 
infusion media (BHI) (Sigma) supplemented with chloramphenicol (10µg/mL) 
(Sigma) and aliquots were frozen at -80oC. Experiments using LmDActA-TB10 
were performed by injecting host mice with 107 bacteria 1 day after 1:1 co-transfer 
of 104 naïve and memory TB10Rg3 cells. Bacterial titers were enumerated by 
plating 10-fold serial dilutions of inoculum onto BHI agarose supplemented with 
chloramphenicol (10µg/mL). 
 
Flow cytometric analysis. Lungs, spleen, and LNs were removed after lung 
perfusion with 10mL of cold RPMI1640. Lung cell suspensions were prepared by 
coarse dissociation using the GentleMACS tissue dissociator (Miltenyi Biotec, 
Germany). Tissue was digested for 30-60 min at 37°C with 250 U/mL collagenase 
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(Sigma) in complete RPMI1640 [10% heat inactivated FCS (Sigma), 10 mM 
HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 10mM b-mercaptoethanol, 50 
mg/ml streptomycin and 50 U/ml penicillin (all from Invitrogen)] followed by 
homogenization in the GentleMACS dissociator and sequential straining through 
70 µm and 40 µm nylon cell strainers (Falcon). Spleen and LN cell suspensions 
were prepared using gentle disruption of the organs through a 70 µm nylon 
strainer, followed by a 40 µm nylon cell strainer. For some experiments, 
erythrocytes were lysed in using a hemolytic solution. For co-transfer experiments 
using naïve and memory TCR Rg CD8+ T cells, CD8+ T cells were enriched prior 
to surface antibody staining using either positive or negative selection (Mouse CD8 
T cell isolation kit or CD8 T cell isolation kit II, Miltenyi Biotec). Surface staining 
was performed with antibodies specific for mouse CD3ε (clone 145-2C11), CD4 
(clone GK1.5), CD8 (clone 53-6.7), CD19 (clone 6D5), CD44 (clone IM7), CD62L 
(clone MEL-14), CD127 (clone A7R34), KLRG1 (clone 2F1/KLRG1), CXCR3 
(clone CXCR3-173), CD45.1 (clone A20), CD45.2 (clone 104), CD90.1 (clone OX-
7), CD90.2 (clone 53-2.1), Va2 (clone B20.1), Vb11 (clone KT11) (all from 
Biolegend, CA, USA). TB10.44 11-loaded and B8R20 27-loaded H-2Kb tetramers 
were obtained from the National Institutes of Health Tetramer Core Facility (Emory 
University Vaccine Center, Atlanta, GA, USA). For most experiments, duel-
tetramer staining was performed as described (Moon et al., 2009) using PE- and 
APC-conjugated TB10.44 11-loaded tetramers together to accurately enumerate 
low-frequency events and minimize false-positive signal. For adoptive co-transfer 
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experiments, an amine-reactive viability dye, Zombie Aqua (Biolegend) was used 
to exclude necrotic cells. The active caspase-3 apoptosis antibody kit was 
measure apoptosis (clone C92-605, Beckton Dickinson, CA). All samples from 
Mtb-infected mice were fixed with 1% paraformaldehyde before analysis. Data 
were acquired using a FACS Canto II (Becton Dickinson) or a MACSQuant flow 
cytometer (Miltenyi Biotec). Data were analyzed using FlowJo Software V9 (Tree 
Star, OR). For both analysis and cell sorting, single-lymphocyte events were gated 
by forward scatter area and height versus side scatter area for size and granularity.  
 
Adoptive T cell transfer of CD8+ T cells. Single cell suspensions of homogenized 
spleens and LNs (inguinal, cervical, axillary, mediastinal, and mesenteric) were 
prepared from vaccinated retrogenic mice (8-12 weeks after the last vaccination) 
or age-matched unvaccinated mice. CD8+ T cells were purified by negative 
selection using the CD8+ T cell isolation kit II (Miltenyi Biotec) or the EasySep™ 
mouse CD8 T cell enrichment kit (StemCell Technologies, Vancouver, BC, 
Canada) followed by magnetic separation. After purification, cells were stained 
with eFluor 450 proliferation dye (eBiosciences), antibody-stained and sorted by 
flow cytometry to achieve uniform populations of naïve or memory CD8+ T cells. 
For TB10Rg3 naïve/memory co-transfer experiments, 1x104 cells of each 
population were mixed at a 1:1 ratio (confirmed by flow cytometry) and were 
transferred IV into congenic recipients (CD90.1 or CD45.1), which had been 
infected 0-7 d earlier with Mtb. TB10Rg3 CD8+ T cells used for the memory group 
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were generated on the Thy1.1+, CD45.1+, and Thy1.2+CD45.2+ backgrounds to 
ensure that none of the observed effects were specific to congenic backgrounds 
of the mice. For protection experiments, 1x105 TB10Rg3 Thy1.2+CD45.2+ memory 
or naïve cells were transferred into TCRa /  mice or sub-lethally irradiated (600 
Rads) C57BL/6 mice, and challenged with Mtb the same day.  
 
Cell sorting. Fluorescent antibody-stained cells were sorted using a FACS Aria II 
(Becton Dickinson) flow cytometer. For adoptive transfer experiments, CD8+CD4
GFP+Va2+ KLRG1Lo CD44h  memory (from vaccinated Rg mice) or CD44Lo naïve 
TB10Rg3 cells (from age-matched unvaccinated Rg mice) were sorted from pre-
enriched CD8+ T cells. For TCRb repertoire analysis, we used duel-tetramer 
staining to identify and sort CD8+CD4 tetramer++CD44H  T cells from blood, one 
week after vaccination with amphi-TB10/CD40/poly(I:C). Twelve weeks after 
vaccination, the same mice were infected with Mtb, and five weeks later, 
CD8+CD4 tetramer++CD44H  T cells were again sorted from the lungs.  
 
Intracellular cytokine staining and ELISAs. Lung cells cultured with rhIL-2 (100 
U/mL; Peprotech) were stimulated in the presence or absence of TB10.44 11 
peptide (10 µM; New England Peptides) or αCD3/αCD28 mAbs (1 mg/mL, 
BioLegend) as positive control. After 1 h at 37ºC, GolgiStop (BD Pharmingen, CA, 
USA) was added for 4 h. Cells were then stained with antibodies, permeablized 
(BD Permwash Kit; BD Pharmingen), and stained for IFNγ (clone XMG1.2; 
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Biolegend), TNF (clone MP6-XT22; Biolegend), or Granzyme B (clone GB11; 
Biolegend). For ELISAs, IFNγ, TNF, and IL-2 production were measured in 
supernatants after 48h stimulation with peptide, using ELISA Max standard kits 
(Biolegend).  
 
In vivo CTL assay. Cytotoxicity was determined using peptide-coated splenocytes 
from congenic CD45.1+ B6 mice as target cells, differentially-labeled with the cell 
proliferation dyes eFluor 450 (eBiosciences) and/or CFSE (eBiosciences) as 
previously described (Woodworth et al., 2008). Briefly, target cells were pulsed 
with 10 µM, 1 µM, 0.33 µM, 0.1 µM, 0.033 µM, or 0.01 µM of TB10.44 11 peptide, 
or left unpulsed (as control). Six of the target cell populations were then labeled 
with 5 µM, 1.25 µM, or 0.3125 µM eFluor 450 dye (two populations for each dye 
concentration). Prior to washing, three of the six populations (one for each of the 
eFluor 450 dye concentrations) were also labeled with 5 µM CFSE. The 7th 
population of peptide-coated targets was stained only with 5 µM CFSE. After 
extensive washing, labeled populations were mixed at equal cell ratios and 3-5 x 
106 cells per population (21-35 x 106 total cells) were injected into 
TB10/CD40/poly(I:C)-vaccinated or unvaccinated control CD45.2+ B6 mice. After 
20h, the relative proportions of each populations in the lung and spleen were 
determined by flow cytometry and compared unvaccinated control mice as 
described (Woodworth et al., 2008).  
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Measurement of cell proliferation. Analysis TB10Rg3 cell proliferation was 
measured after adoptive transfer into Mtb-infected, vaccinated, or TCRa /  mice, or 
in vitro after stimulation by labeling purified TB10Rg3 CD8+ T cells with 5 µM of 
the cell proliferation dye eFluor 450 (eBiosciences). Proliferation, as measured by 
dye dilution, was measured by flow cytometry in vivo 11d after aerosol Mtb 
infection, or in vitro 64h after co-culture with APCs coated with a serial dilution of 
TB10.44 11 peptide. Cell proliferation at later time points (d15 or d18) in vivo was 
assayed by the incorporation of the synthetic thymidine analogue 5-Ethynyl-2’-
deoxyuridine (EdU, Life Technologies). Briefly, 1mg EdU diluted in 100 µL PBS 
was injected i.p. into each mouse 12h prior to analysis. After antibody staining, 
single cells suspensions were assayed for EdU incorporation using the Click-iT 
EdU Alexa Fluor 647 Flow Cytometry Assay kit (Life Technologies). 
 
Statistical analysis. Data are represented as mean ± SEM. A two-tailed student’s 
t-test was used for normally-distributed data to compare two groups. One-way or 
Two way ANOVA were used to compare more than two groups, followed by 
Bonferroni or Sidak post-tests. A p value < 0.05 was considered to be statistically 
significant. Statistical analyses were performed using Prism V6 (GraphPad 
Software, San Diego, CA).  
 
  
	 	 	 64	
Preface to Chapter III 
 
This chapter has been adapted from the recently published manuscript by 
Carpenter et al in PLoS Pathogens: 
 
Carpenter, S. M., Nunes-Alves, C., Booty, M. G., Way, S. S., & Behar, S. M. 
(2016). A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness 
Cost That Is Modified by TCR Affinity during Tuberculosis. PLoS Pathogens, 
12(1), e1005380. http://doi.org/10.1371/journal.ppat.1005380 
 
 
Additional figures have been including, and the figure numbers are different from 
those in these published manuscripts. This manuscript represents the second part 
of the thesis project of Stephen Carpenter, who designed and performed the 
experiments, analyzed the data, and wrote the manuscript with contributions from 
co-authors and mentorship from Dr. Samuel Behar.  
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CHAPTER III 
 
Deep sequencing of memory CD8+ T cell receptors reveals selection of 
specific TCR motifs during TB 
 
Introduction 
Memory T cells are thought to provide a faster response that is armed to 
exert a potent effector response against infected cells (Jameson and Masopust, 
2009). However, the ability to distinguish the memory-derived effectors (2o 
response) from naïve-derived effector T cells (1o response) during their response 
to infection has been nearly impossible by conventional methods. While the 
magnitude of the 1o and 2o responses can be estimated by comparing the 
frequency of antigen-specific T cells in vaccinated (or unvaccinated) test subjects, 
the origin of the individual effector T cells in vaccinated individuals remains 
obscure. Surface markers are largely unhelpful in distinguishing the two groups, 
as both 1o and 2o responses become activated after challenge. Adoptive transfer 
of congenically-marked cells into infected animals has been the most common 
method used to study memory T cells during infection (Jabbari and Harty, 2006). 
We use this technique heavily in Chapter 2. However, this system has 2 main 
drawbacks for studying natural responses to infection: First, it is difficult to study 
polyclonal populations of T cells due to concern for altering the function of antigen-
specific T cells with the use of tetramers during sorting. Second, the composition 
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of the memory T cell cohort may not be physiologic, as the ratios of various 
memory T cell subsets depends on the organs from which they were isolated (e.g. 
central vs. effector vs. tissue-resident memory) prior to adoptive transfer (Steinert 
et al., 2015), and only 1-10% are estimated to “take” after injection (Plumlee et al., 
2013). The adoptive transfer method is not a fair direct comparison of memory and 
naïve T cells, unless both are derived from TCR transgenic (or retrogenic) mice 
and co-transferred. However, if T cells can be sampled both after vaccination and 
during infection in the same individual, TCR sequencing can be used to track the 
expansion and abundance of clonotypes derived from both memory or naïve T 
cells. 
In this chapter, we use next generation sequencing of T cell receptors to 
both quantify and track individual T cell clonotypes to estimate the roles and 
behavior of the TB10.4-specific 1o and 2o CD8+ T cell responses in the lungs of 
vaccinated mice after Mtb challenge. At the peak of the CD8+ T cell response to 
amphi-TB10 / aCD40 / poly(I:C) vaccination (1 week), we use tetramers to flow-
sort antigen-specific T cells from the blood of vaccinated mice (Fig 3.1). After the 
development of memory (12 weeks), we challenge vaccinated mice with aerosol 
Mtb, and again isolate TB10.4-specific CD8+ T cells from the lungs of vaccinated 
mice, followed by sequencing of the T cell receptors in all groups (Fig 3.1). Using 
TCRb deep sequencing, we find enormous clonotypic diversity in the TB10.4-
specific CD8+ T cell response to vaccination, but after Mtb challenge the 2° 
response undergoes selection for a specific TCR motif that we attribute to higher 
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affinity. By comparing the response of two different TCRs that differ in their affinity 
for the same epitope, we show that memory-derived CD8+ T cells with an 
increased affinity for antigen have greater fitness, demonstrating that TCR-
dependent factors promote successful continued expansion of 2° effector CD8+ T 
cell responses during chronic infection in the lung. 
By adoptively transferring well-characterized naïve and memory TB10Rg3 
CD8+ T cells at a 1:1 ratio, we showed that factors other than TCR affinity or 
abundance determined the increased fitness of the naïve T cell response. On the 
other hand, our experiments using TB10Rg4 CD8+ T cells, which recognize the 
same epitope as TB10Rg3, but with a higher affinity, indicate that increased affinity 
can offset the disadvantage in the expansion rate of memory CD8+ T cells leading 
to their dominance over lower-affinity naïve CD8+ T cells during Mtb challenge. In 
reality, there exists considerable variation in frequency and TCR affinity in the T 
cell repertoire, which could affect the success of individual clonotypes. Although 
impossible to track the fates of memory T cells during infection using flow 
cytometry alone, we use deep sequencing of the TCRs to study memory CD8+ T 
cells specific for TB10.4 from vaccinated mice during tuberculosis. Using TCRb 
sequencing, we evaluate the clonality, relative abundance, and TCRb repertoire of 
memory-derived CD8+ T cells during Mtb challenge.  
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Results 
TCRb deep sequencing distinguishes primary and secondary T cell 
responses 
To determine how Mtb infection affects the ability of TB10-specific memory 
CD8+ T cells to expand in mice with an intact and diverse immune repertoire, we 
used NexGen TCRb sequencing to track the polyclonal TB10-specific CD8+ T cell 
response to vaccination, and the subsequent recall response after Mtb challenge 
in individual mice. We reasoned that TCRb clonotypes elicited by vaccination that 
were also detected after challenge represented 2° effectors. On the other hand, 
clonotypes detected only after challenge were more likely to be part of a new 1° 
response. We purified TB10-specific CD8+ T cells using tetramers by flow sorting 
after vaccination, and again after Mtb challenge in the same individual, and 
sequenced their TCRb repertoire (Fig 3.1). We find that after vaccination, the 
clonality of TB10-specific CD8+ T cells was not statistically different than that of 
total T cells from the peripheral blood of uninfected B6 mice (Fig 3.2a). However, 
TB10-specific CD8+ T cells were significantly more diverse after vaccination than 
after Mtb challenge (Fig 3.2a). Thus, the post-challenge TCRb repertoire was more 
similar to what we observed following primary Mtb infection (Nunes-Alves et al., 
2015). Interestingly, the TB10-specific CD8+ T cells appeared to be less clonal 
after Mtb infection in mice that were previously vaccinated [compare ‘challenged’ 
vs. ‘primary Mtb’; ‘primary Mtb’ data from (Nunes-Alves et al., 2015)], raising the 
possibility that vaccination leads to a more diverse T cell response during infection.   
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Figure 3.2: TCRb deep sequencing reveals the dual contribution of the primary and 
secondary effector CD8+ T cell response in vaccinated mice challenged with Mtb. 
(a) Clonality of TB10-specific CD8+ T cells from blood 1w after amphi-TB10 vaccination, 
compared to those isolated from lung in the same individuals 4-5w after Mtb challenge, or 
compared to those isolated from unvaccinated, Mtb-infected mice [data for primary Mtb-
infected mice from (Nunes-Alves et al., 2015)]. Data are from 3-10 individuals/group, 
independently analyzed from two independent experiments. One-way ANOVA with a 
Bonferroni post-test was used to compare clonality. * p < 0.05, **** p < 0.0001. (b) Sharing 
of unique TCRb DNA sequences between the post-vaccination (blood) and post-Mtb 
challenge (lung) repertoires of TB10-specific CD8+ T cells. Numbers are the average of 
unique TCRb DNA clonotypes, determined for four subjects, each analyzed individually. 
(c) The percentage of the lung TB10-specific CD8+ TCRs detected either only post-Mtb 
challenge (e.g., 1° response); or, detected both post-vaccination and post-Mtb challenge 
(e.g., 2° response). Left, unique clonotypes; center, total TCRs; right, total TCRs that had 
a frequency of >0.5%.  
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One week after vaccination, we detected 2254 ± 509 unique clonotypes 
among peripheral blood TB10-specific CD8+ T cells (Fig 3.2b). Four weeks after 
Mtb challenge, the repertoire of pulmonary TB10-specific CD8+ T cells consisted 
of 652 ± 125 unique clonotypes. On average, 56% (362 ± 71) of the unique 
clonotypes in the lungs of infected mice were previously detected after vaccination, 
meeting our definition of 2° effector T cells. Thus, nearly half of the distinct 
clonotypes specific for TB10.4 in the lungs of vaccinated mice challenged with Mtb 
were part of a new 1° response. However, not all clonotypes were similarly 
represented in the lung. While the shared sequences, which we define as 2° 
effectors, accounted for 56% of the unique clonotypes, they added up to 81% of 
all TB10-specific CD8+ T cells in the lung. A possible bias in our analysis is that 
clonotypes detected in the lung might not be detected in blood. However, the 
peripheral blood samples in this cohort of mice were sequenced at the maximum 
depth available to mitigate this possible confounder. We have found the naïve 
precursor frequency of TB10-specific CD8+ T cells in C57BL/6 mice to be ~1 in 
20,000 (0.005%) (Nunes-Alves et al., 2015), whereas the frequency of memory 
TB10-specific CD8+ T cells 8-12 weeks after a single vaccination with amphi-TB10 
/ aCD40 mAb / poly(I:C) is ~1:10 (Fig 2.2b). Therefore, we focused on only the 
abundant clonotypes in the lung, using a threshold of 0.005% or 0.5%, and we 
found that 84% and 81% of the total TCRs were shared, which is similar to when 
clonotypes of all frequencies are analyzed (Fig 3.2c). Thus, in vaccinated mice 
subsequently challenged with Mtb, nearly half of the unique clonotypes in the lung 
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represent a new 1° response and in aggregate they make up ~20% of the total 
TB10-specific CD8+ T cells in the lung. Since the TB10-specific response 
represents >30% of all CD8+ T cells in the lung by 4wpi, the new 1o response 
expanded from ~1 in 20,000 CD8+ T cells (in the naïve repertoire) to ~6% of the 
CD8+ T cells in the lung. Likewise, the 2o response expanded from ~1 in 10 CD8+ 
T cells (in the post-vaccination repertoire) to ~24% of the CD8+ T cells in the lung. 
Thus, the new 1o response underwent a ~1,200-fold expansion compared to a 
~2.4-fold expansion for the 2o response. 
 
TCRb deep sequencing identifies TB10-specific CD8+ T cell clonotypes that 
are shared between lung and blood 
Our evaluation of the post-vaccination and post-Mtb challenge TCR 
repertoires in the same individual requires the comparison of T cells in blood (post-
vaccine) to lung (post-challenge). To further validate this approach, we asked to 
what degree the TB10-specific repertoire in the blood and lung are related. TB10-
specific CD8+ T cells (e.g., tetramer+) were simultaneously isolated from the 
peripheral blood and perfused lung of individual Mtb-challenged mice by flow 
sorting. Although unique clonotypes exist that are detected only in lung or blood, 
all of the abundant TCR clonotypes detected in the lung (defined as a frequency 
>0.5%) were also detected in blood (Fig 3.3a). In each of the mice, two distinct 
clusters of T cell clonotypes could be identified: each with a similar frequency in 
blood but significantly different frequencies in lung. Although lung parenchymal 
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and lung intravascular pools of T cells were not formally distinguished in this 
experiment, T cells in these newly-defined compartments might also exhibit such 
clustering by frequency in the lung (Moguche et al., 2015; Sakai et al., 2014b).  
There was substantial overlap between the clonotypes detected in blood 
and in lung (Fig 3.3a,b). We detected 400-600 distinct DNA sequences among 
pulmonary TB10-specific CD8+ T cells (Fig 3.3b). Of these unique sequences, 30% 
were also detected in the blood, and the remaining 70% were detected only in the 
lung (Fig 3.3c). Many of the clonotypes unique to the lung compartment were 
infrequent and in aggregate accounted for only 10% of the total T cells. Thus, 90% 
of the TB10-specific CD8+ T cells found in the lungs of infected mice used TCRs 
that were detected both in blood and in lung (Fig 3.3c). In fact, if only the highly 
abundant clonotypes (>0.5%) are considered, more than 99% of pulmonary TB10-
specific CD8+ T cells use a TCR that is detected in peripheral blood during 
infection. Thus, clonotypes that are abundant and clonally expanded in the lung 
are also detected in peripheral blood.   
	 	 	 74	
 
 
 
 
 
 
Figure 3.3: The distribution of the TB10-specific CD8+ T cell receptor repertoire in 
lung and blood after aerosol Mtb challenge in vaccinated mice. (a) Representative 
logarithmic scatter plot showing the frequencies of all clonotypes detected in the blood or 
in the lung of a single individual 5 weeks after Mtb challenge. Green, lung only; Red, blood 
only; Blue, Shared. The dotted lines indicate frequencies of 0.005% and 0.5%, 
respectively. (b) Sharing of unique TCRb DNA sequences between blood and lung 
repertoires of TB10-specific CD8+ T cells in individual mice, 5 weeks after infection. 
Numbers are the average of unique TCRb DNA clonotypes, determined for three subjects 
analyzed individually. (c) The percentage of the lung repertoire of TB10-specific CD8+ 
TCRs that were detected only in the lung (“lung only”) or detected in the blood and lung 
(“shared with blood”) after Mtb challenge. Left, unique clonotypes; right, total TCRs. Only 
clonotypes with a frequency of >0.005% were analyzed.  
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Selection drives T cell expansion following Mtb infection 
To compare the fitness of each TCR clonotype responding to TB10.4 after 
Mtb challenge, we analyzed matched blood (post-vaccination) and lung (post-Mtb 
challenge) samples from individual subjects. Each unique TCRb DNA sequence 
detected in the post-vaccination and post-challenge repertoire of the same 
individual were classified as “successful” if they increased in frequency after Mtb 
challenge or “persisters” if they decreased, but remained present post-challenge. 
Clonotypes were stratified as “de novo” or “unsuccessful” if they were present 
only after Mtb challenge or vaccination, respectively (Fig 3.4a). Interestingly, the 
two-thirds of the unique clonotypes elicited by vaccination are “unsuccessful” and 
are not detected after infection (Fig 3.4b). Although this is a large number of unique 
TCR sequences, they represent only ~18% of the total TB10-specific CD8+ T cell 
response in peripheral blood (Fig 3.4b). Conversely, after Mtb challenge, 25% of 
the unique clonotypes in the lung were de novo sequences, which accounted for 
~16% of the total TB10-specific CD8+ T cells in lung (Fig 3.4a). Although each of 
these TCRs generally had a frequency of <0.5%, occasionally they were at a 
higher abundance (see Fig 3.4a as an example). Thus, although the naive T cells 
have the potential to expand more than memory T cells (Fig 2.5e,f, and (M. D. 
Martin et al., 2012; Mehlhop-Williams and Bevan, 2014; Miyakoda et al., 2012; 
West et al., 2011)) and make a definable contribution to the recall response to Mtb 
infection, the majority of the total TCRs responding to Mtb challenge are a clonal 
population of 2° effectors derived from a relatively small number of “successful” 
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vaccine-elicited T cells (Fig 3.4b). Finally, the majority of the vaccine-elicited T cells 
(67%) fail to expand during Mtb challenge, becoming “persisters” (Fig 3.4b). The 
fates of these “successful” and “persister” TCRs mirror the observed functions of 
the higher-affinity TB10Rg4 and lower-affinity TB10Rg3 CD8+ T cells, respectively, 
in our adoptive transfer studies (Fig 3.4b and Fig 2.11a,b).  
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Figure 3.4: Selection drives the expansion of TB10-specific CD8+ T cells. (a) 
Representative logarithmic scatter plot showing the frequencies of all clonotypes detected 
in the post-vaccination (blood) or in the post-Mtb challenge (lung) repertoire of TB10-
specific CD8+ T cells. Green, lung only (de novo response); red, blood only (unsuccessful); 
blue, shared (persistent & successful). The diagonal dashed line separates the successful 
and the persistent clonotypes. The dotted lines indicate frequencies of 0.005%, 0.5%, and 
3%. (b) The proportion of total TCRb amino acid sequences categorized as 
“unsuccessful”, “persisters”, “successful”, or “de novo” as defined in the text, from the post-
vaccination (blood, left) or post-Mtb challenge (lung, right) repertoires. Top row, unique 
clonotypes; bottom row, total TCRs. Only clonotypes with a frequency of >0.005% were 
analyzed. (c) CDR3b length distribution among unique clonotypes categorized as 
“unsuccessful”, “persisters”, “successful”, or “de novo”.  
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Our clonality data suggested that infection was driving greater selection 
than vaccination. To identify structural features that govern TCR success or failure, 
we analyzed the CDR3b amino acid sequence of “persisters” and “successful” 
TCRb clonotypes detected in the post-vaccination and post-challenge repertoire 
of the same individual. The CDR3b length distribution was similar among these 
four groups, with 14 amino acids being the most common length (Fig 3.4c). To 
focus on selection, we analyzed clonotypes that were present in both the post-
vaccination and post-Mtb challenge repertoire, with a frequency of >0.5% in one 
of the samples. In addition, we restricted our analysis to clonotypes with a CDR3b 
length of 13, 14, or 15, which accounted for most of the sequences (Fig 3.4c). We 
identified 241 sequences from 7 individual subjects that met these criteria. These 
highly-represented clonotypes accounted for 60% of the productive sequences 
detected in the lungs of mice after Mtb challenge. Analysis showed that the 
“successful” clonotypes had a “DRxN” CDR3b motif (Fig 3.5). The “DRENSD” 
motif, which had previously been detected among TB10-specific CD8+ T cells after 
Mtb infection in the absence of vaccination (Nunes-Alves et al., 2015), was 
expressed by the most successful clones (Fig 3.5). In contrast, “persister” clones 
lacked the “DRENSD” motif and instead more frequently encoded “RG” (Fig 3.5). 
A similar motif was identified among those clonotypes with a CDR3b length of 15 
amino acids. The persisters had a motif of “DRggNx”, while the successful clones 
had a motif of “DRgNQD” (Fig 3.5). Therefore, during Mtb infection, selective 
pressure constrains structural features of the TCR repertoire that recognize TB10.   
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Figure 3.5: High consensus among CDR3b sequences from “successful” memory 
TB10-specific CD8+ T cells. CDR3b amino acid motifs were determined for highly 
prevalent clonotypes (>0.5% in post-vaccination or post-Mtb challenge repertoire), which 
were identified as “persisters” or “successful” TCR clonotypes with a CDR3 length of 13, 
14, or 15 aa. For successful TCRs, different frequency thresholds were chosen (0.5%, 
2%, or 3%) to identify structural motifs among highly prevalent clonotypes. The numbers 
below each sequence refer to the number of unique clonotypes that were used to derive 
the motif and the average frequency of each clonotype among total productive sequences. 
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Discussion: 
We have shown that TB10-specific CD8+ T cells are under extreme 
selection, and clonal expansions emerge even early during infection. Given our 
data from the study of naïve and memory TCR retrogenic CD8+ T cells specific for 
TB10.4 (Chapter 2 and (Nunes-Alves et al., 2015)) we infer the observed clonal 
selection of presumably high-affinity T cells is driven by a paucity of antigen 
presentation. Although we have not yet directly correlated these memory T cell 
clonotypes with function, we hypothesize that these same conditions could lead to 
memory T cell dysfunction during Mtb challenge.  
TCR deep sequencing allowed us to track vaccine-elicited memory T cells 
during active infection. We were able to compare their expansion with that of a 
new primary response to infection, and determine the most successful T cell clones 
by their expansion. However, we had two initial concerns with this technique. First, 
we wondered whether the T cells sampled in the blood after vaccination would 
accurately represent the entire repertoire of memory T cells that could respond to 
infection. By sampling a large volume of blood after vaccination, and increasing 
the depth of sequencing, we were able to detect both highly abundant clonotypes 
as well as those at such low frequency as to be on par with the naïve precursor 
frequency for TB10.4-specific CD8+ T cells in C57BL/6 mice (~1:20,000). Second, 
we questioned the congruence between the TCR repertoire found in the lung and 
the blood. However, by sequencing tetramer+ T cells from both the blood and lung 
during infection, we found >90% overlap of the total TCRs between lung and blood. 
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We were able to detect ~81% of the memory T cell sequences found post-
vaccination in the lung during TB. While it is possible that we missed some of the 
post-vaccination clonotypes in the remaining 19% found post-infection, it is 
statistically unlikely that we missed dominant clones unless nearly all of the T cells 
in a particular clonotypes were inaccessible by the blood compartment (Steinert et 
al., 2015).  
The majority of the unique TCR clonotypes detected in the lungs of infected 
mice were initially detected post-vaccination. Interestingly, the dominant 
clonotypes were all derived from a narrow repertoire, suggesting that they were 
undergoing selection based on their affinity or other structural features during the 
response to Mtb infection. One such structural feature is the dominant TCRb motif 
“DRENSD” that we find among TB10-specific CD8+ T cells in the lungs post Mtb-
challenge (in our vaccinated mice), and is the same motif we previously identified 
in unvaccinated Mtb-infected mice (Nunes-Alves et al., 2015), representing a 
highly-clonal response to Mtb. Thus, this motif appears to be highly-selected and 
independent of vaccination. We have shown that TB10-specific CD8+ T cells 
undergo massive clonal expansion in Mtb-infected mice, characterized by 
selection of the CDR3β motif, “DRENSD,” most likely driven by avidity for the 
TB10.44 11/Kb complex, a hypothesis that we are preparing to test directly (Cukalac 
et al., 2014; Nunes-Alves et al., 2015). Interestingly, the majority of the clonotypes 
in the blood after vaccination were “persisters”, in that they did not increase in 
frequency relative to their abundance 1w post-vaccination in blood. Thus, the 
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majority of vaccine-elicited TB104 11-specific CD8+ T cells persist without 
expanding significantly during tuberculosis, and we relate this phenomenon to that 
observed after adoptive transfer of memory TB10Rg3 (lower affinity) CD8+ T cells 
into Mtb-infected mice, which are impaired in their expansion during TB. However, 
the higher-affinity TCR Rg CD8+ T cells (TB10Rg4) could be compared to a 
“successful” clonotypes from the TCR sequencing data as they displayed improved 
expansion in response to Mtb infection. 
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Materials and Methods 
 
Mice. C57BL/6J mice were purchased from Jackson Laboratories (Bar Harbor, 
ME) and housed under specific pathogen-free conditions at the University of 
Massachusetts Medical School animal facilities. Mice were 7 to 10 weeks old at 
the start of all experiments. Infected mice were housed in biosafety level 3 facilities 
under specific pathogen-free conditions at UMMS.  
 
Vaccination and elicitation antigen-specific CD8+ T cells. “Amphi-TB10” 
(MFVMFVQIMYNYPAM) peptide was purchased from New England Peptides 
(Gardner, MA, USA) and reconstituted in DMSO (10mM). High molecular weight 
polyinosinic:polycytidylic acid [poly(I:C)] was obtained from InvivoGen (San Diego, 
CA). Anti-CD40 mAb (clone FGK4.5) was purchased from BioXCell (West 
Lebanon, NH). Vaccines were prepared by mixing 100 micromoles of peptide, 50 
µg poly(I:C), and 50 µg aCD40 mAb, in a total volume of 200 µL sterile PBS and 
administered intravenously. Peripheral blood TB10.44 11-specific CD8+ T cell 
responses were sorted by flow cytometry 1 week after vaccination. Mice were 
rested 12 weeks after vaccination to allow for the development of memory. Mice 
were then challenged with aerosol Mtb infection and the secondary response was 
assessed in the lungs by TCRb deep sequencing 4-5 weeks post Mtb-challenge. 
 
Experimental infection. Mtb (strain Erdman) infections were performed via the 
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aerosol route using a Glas-Col full body inhalation exposure system (Terre Haute, 
IN). 1mL Mtb Erdman culture was thawed from a frozen stock of broth culture in 
Middlebrooke 7H9 medium frozen at -80oC at mid-log phase growth. The same 
frozen stock was used for all experiments. Mice received an inoculation dose of 
100-150 CFU/mouse, as measured within 24 hours of infection. At 4-5 weeks post-
infection, mice were euthanized, lungs were aseptically removed, individually 
homogenized for T cell isolation. The inoculum was quantified in control mice 1 
day after aeorosol inoculation by plating neat lung homogenate onto 7H11 agar 
plates.  
 
Flow cytometry and cell sorting. Lungs were removed after perfusion of 
pulmonary arteries with 10mL of cold RPMI1640. Lung cell suspensions were 
prepared by coarse dissociation using the GentleMACS tissue dissociator (Miltenyi 
Biotec, Germany). Tissue was digested for 30-60 min at 37°C with 250 U/mL 
collagenase (Sigma) in complete RPMI1640 [10% heat inactivated FCS (Sigma), 
10 mM HEPES, 1 mM sodium pyruvate, 2 mM L-glutamine, 10mM b-
mercaptoethanol, 50 mg/ml streptomycin and 50 U/ml penicillin (all from 
Invitrogen)] followed by homogenization in the GentleMACS dissociator and 
sequential straining through 70 µm and 40 µm nylon cell strainers (Falcon). CD8+ 
T cells were enriched prior to surface antibody staining using positive selection 
(Mouse CD8 T cell isolation kit, Miltenyi Biotec) followed by magnetic separation. 
Surface staining was performed with antibodies specific for mouse CD3ε (clone 
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145-2C11), CD4 (clone GK1.5), CD8 (clone 53-6.7), CD19 (clone 6D5), CD44 
(clone IM7) (all from Biolegend, CA, USA). TB10.44 11-loaded H-2Kb tetramers 
were obtained from the National Institutes of Health Tetramer Core Facility (Emory 
University Vaccine Center, Atlanta, GA, USA). Duel-tetramer staining was 
performed as described (Moon et al., 2009) using PE- and APC-conjugated 
TB10.44 11-loaded tetramers together to accurately enumerate low-frequency 
events and minimize false-positive signal. We sorted CD8+CD4 tetramer++CD44H  
T cells from blood, one week after vaccination with amphi-TB10/CD40/poly(I:C). 
Twelve weeks after vaccination, the same mice were infected with Mtb, and 4-5 
weeks later, CD8+CD4 tetramer++CD44H  T cells were again sorted from the lungs. 
An amine-reactive viability dye, Zombie Aqua (Biolegend), was used to exclude 
necrotic cells. All samples from Mtb-infected mice were sorted using a FACS Aria 
II under BSL-3 conditions, followed by genomic DNA extraction. DNA samples 
were heated to 85oC for 1 hour to kill any remaining bacteria prior to removing 
samples from the BSL-3. 
 
Next generation sequencing. Genomic DNA was purified from sorted TB10 
tetramer+ CD44+CD8+ T cell populations using the QIAamp DNA Mini kit (Qiagen). 
High-throughput TCRβ sequencing was performed by Adaptive Biotechnologies 
Corp. (Seattle, WA) (http://www.immunoseq.com) and analyzed using the 
ImmunoSEQ analyser toolset (Lepore et al., 2014). Clonality was calculated 
as entropy of the frequency distribution 1-(entropy/log2[# unique TCRs]). Entropy, 
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a measure of diversity within a complex data set, is also known as the Shannon-
Wiener index, Shannon’s diversity index or Shannon’s entropy (Sherwood et al., 
2013; Stewart et al., 1997). Transforming entropy in this manner results in a 
clonality score on a scale between 0-1. A score of “0” indicates that every TCR is 
unique; a score of “1” means that every TCR is the same. WebLogo 3 was used 
to identify CDR3b motifs (http://weblogo.threeplusone.com). S6 Supporting 
Information identifies the different samples, their characteristics, and their inclusion 
in the different analyses and figures. 
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Preface to Chapter IV 
 
This chapter comprises the discussion of the work in the dissertation. The 
discussion includes both new, original text, as well as text from three recently 
published manuscripts, written by Stephen Carpenter, including: 
 
Carpenter, S. M., Nunes-Alves, C., Booty, M. G., Way, S. S., & Behar, S. M. 
(2016). A Higher Activation Threshold of Memory CD8+ T Cells Has a Fitness 
Cost That Is Modified by TCR Affinity during Tuberculosis. PLoS Pathogens, 
12(1), e1005380. http://doi.org/10.1371/journal.ppat.1005380 
 
Behar, S. M., Carpenter, S. M., Booty, M. G., Barber, D. L., & Jayaraman, P. 
(2014). Orchestration of pulmonary T cell immunity during Mycobacterium 
tuberculosis infection: immunity interruptus. Seminars in Immunology, 26(6), 
559–577. http://doi.org/10.1016/j.smim.2014.09.003  
 
Nunes-Alves, C., Booty, M. G., Carpenter, S. M., Jayaraman, P., Rothchild, A. 
C., & Behar, S. M. (2014). In search of a new paradigm for protective immunity to 
TB. Nature Reviews Microbiology, 12(4), 289–299. 
http://doi.org/10.1038/nrmicro3230  
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CHAPTER IV  
 
Discussion 
 
It is unclear why vaccinated individuals, or those with prior Mtb infection, do 
not reliably exhibit protection from Mtb reinfection (Fine, 1995; Millet et al., 2013; 
van Rie et al., 1999). An often-cited benefit of recall immunity is its speed 
compared to naïve T cell responses, as shown during acute viral infection 
(Kedzierska et al., 2006), homeostatic proliferation (Sprent and Tough, 1994) and 
sterile antigen stimulation (Veiga-Fernandes et al., 2000). Both memory and naïve 
CD8+ T cells have been shown to expand equally well early during acute 
inflammation and in the presence of abundant antigen (M. D. Martin et al., 2012; 
Mehlhop-Williams and Bevan, 2014). However, the contribution of memory T cells 
may decline under certain circumstances (M. D. Martin et al., 2012; Mehlhop-
Williams and Bevan, 2014; Miyakoda et al., 2012). West et al. find that memory 
CD8+ T cells proliferate poorly during a model of chronic infection (LCMV clone 
13), possibly because persistently high antigen loads induce T cell exhaustion 
(West et al., 2011). Mehlhop-Williams and Bevan find that following vaccination 
with immune-complexed ovalbumin (OVA), a higher antigen threshold is required 
to trigger proliferation of memory T cells than naïve T cells (Mehlhop-Williams and 
Bevan, 2014). Finally, while memory OT-1 cells outperform naïve OT-1 cells after 
infection with Listeria monocytogenes expressing OVA; naïve OT-1 cells 
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dominated after infection with Plasmodium berghei ANKA expressing OVA 
(Miyakoda et al., 2012). These studies raise the possibility that T cell vaccination 
could fail if the environment during infection hinders the expansion of memory T 
cells, which could minimize their contribution. A common thread in these studies is 
that memory T cells are disadvantaged when antigen is limiting, particularly during 
states of persistent inflammation. One limitation in these studies, however, is the 
use of OT-I cells and microbes engineered to over-express OVA rather than T cells 
specific for native microbial antigens. This study is the first to evaluate the behavior 
of memory CD8+ T cells specific for a native immunodominant Mtb antigen using 
TCR retrogenic CD8+ T cells during infection. Furthermore, using peptide-
challenge in two systems we show that the relative expansion of naïve and 
memory CD8+ T cells is determined by the amount of antigen present in their 
environment. Given the difficulty of developing a vaccine for tuberculosis, the fate 
of Mtb-specific memory T cells during challenge is an important question.  
Early initiation and sustained proliferation of a memory recall response are 
two characteristics that could affect the success of memory T cells during Mtb 
infection. We previously hypothesized that delayed initiation of T cell immunity is 
associated with susceptibility to Mtb (Chackerian et al., 2002). Indeed, even a 
transient delay in T cell priming impairs control of Mtb in the lung (Tian et al., 2005). 
Conversely, vaccinating C3H mice, whose adaptive immune response is delayed 
by ~1 week compared to C57BL/6 mice, with a DNA vaccine promoted an early 
recall response and CD8+ T cell-mediated reduction in bacterial CFU (Y. Wu et al., 
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2008). CD8+ T cell vaccination in CD4 /  mice also led to protection after Mtb 
challenge (Derrick et al., 2004). In contrast, CD8+ T cell vaccination in C57BL/6 
mice did not reduce bacterial CFU after Mtb challenge despite a robust memory 
response to vaccination ((Lindenstrøm et al., 2014) and Figs 2.2a,c, 2.3c). We 
reason this is due to the rapid 1o adaptive immune response outnumbering the 2o 
response, preventing memory T cells from contributing meaningfully to combat 
infection. These studies highlight the potential benefits of an early T cell response 
and higher affinity T cells in controlling Mtb growth; however, the specific 
characteristics critical to the successful expansion of memory T cells during TB 
have not yet been evaluated.  
Our results comparing the relative expansion of TB10Rg3 and TB10Rg4 to 
naïve TB10.4-specific CD8+ T cells during TB show the crucial contribution of TCR 
affinity to the successful expansion of the 2° effector CD8+ T cells. In our adoptive 
co-transfer experiments, the response of memory TB10Rg3 and naïve TB10Rg3 
CD8+ T cells results in domination by the 1° effectors by d21. As naïve and memory 
TB10Rg3 CD8+ T cells use an identical TCR and were co-transferred at a 1:1 ratio, 
factors other than TCR affinity or precursor frequency must affect T cell fitness 
after activation. However, there is enormous TCR diversity in individuals with intact 
immune systems and the success of individual clonotypes can be influenced by 
TCR affinity, particularly in environments characterized by little antigen 
presentation. Thus, in co-transfer experiments using the higher-affinity memory 
TB10Rg4 and naïve TB10Rg4 CD8+ T cells, we also observed skewing in favor of 
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the 1° effector response, but the effect was much smaller. The role of TCR affinity 
is also demonstrated by co-transfer experiments using the higher-affinity memory 
TB10Rg4 CD8+ T cells and the lower-affinity naïve TB10Rg3 CD8+ T cells. Now 
we observe the opposite result: the memory TB10Rg4 cells (which have a higher 
TCR affinity) dominate the response by d21. Importantly, both TB10Rg3 and 
TB10Rg4 were dominant clones isolated from different individuals after aerosol 
Mtb infection (Nunes-Alves et al., 2015). Thus, eliciting memory T cells with high 
affinity for pMHC may make them more likely to successfully compete and expand 
during Mtb challenge. During natural infection in vaccinated individuals, 
competition between memory and naïve T cells of differing affinities is expected to 
occur; therefore, increasing the affinity of memory T cells should improve their 
fitness.  
An important property of memory T cell responses is the increase in the 
number of T cells specific for the eliciting antigen (Schmidt et al., 2008). Thus, the 
speed of the recall response is based in part on the greater precursor frequency 
of T cells that recognize the antigen challenge, independent of any increase in 
proliferative rate. By adjusting the ratio of naïve to memory T cells to a 1:1 ratio in 
our adoptive transfer studies, we control for any effect of T cell frequency. In 
contrast, our TCR sequencing of TB10 tetramer+ T cells from intact mice, post-
vaccination and post-challenge, addresses differences between the 1° and 2° T 
cell responses in individuals in which both the avidity and abundance of individual 
clonotypes is allowed to vary. The majority (>80%) of unique TCR clonotypes 
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obtained from the lungs of infected mice were previously detected post-
vaccination. Interestingly, the dominant clonotypes were derived from a narrow 
repertoire, suggesting that they were undergoing selection based on structural 
features during the response to Mtb infection. We speculate that high affinity is the 
most likely factor that would lead to the selection of these clonotypes. One 
dominant structural TCRb motif observed was “DRENSD”, found among TB10-
specific CD8+ T cells in the lungs post Mtb-challenge (in our vaccinated mice). This 
is the same motif we previously identified as the dominant motif for TB10-specific 
CD8+ T cells that made up the primary response in unvaccinated Mtb-infected mice 
(Nunes-Alves et al., 2015). Overall, we find that both the primary and secondary 
TB10-specific CD8+ T cell responses to Mtb are highly-clonal and share a common 
“public” TCR motif. This motif appears to be highly-selected and independent of 
vaccination.  
For the majority of the experiments in these manuscripts, we used a peptide 
/ aCD40 / poly(I:C) vaccination strategy that induces protection against viral 
infection and promotes tumor eradication (Cho et al., 2011; S. Lee et al., 2012; 
Phoolcharoen et al., 2011). The memory CD8+ T cells produced by using this 
vaccine strategy for TB10.4 were potent cytolytic effectors and cytokine-producers, 
and were able to attenuate infection when transferred to immunocompromised 
mice. Two other CD8+ T cell vaccines aimed at individual Mtb epitopes have also 
lowered bacterial burdens in intact mice, although the vaccinated hosts had a 
delayed adaptive immune response (Y. Wu et al., 2008) or were deplete of CD4+ 
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T cells (Derrick et al., 2004). A similarly potent vaccination strategy that elicits 
TB10-specific CD8+ T cells failed to protect intact mice against Mtb challenge 
(Lindenstrøm et al., 2014). In no TB vaccines, CD4 or CD8-focused, however, do 
we observe continued decline of bacterial CFU in the lungs, indicative of 
continuously functional T cells. Lindenstrøm et al. attribute the lack of protection to 
limited presentation of the TB10.44 11 epitope by infected cells during priming due 
to inefficient proteolytic cleavage of the TB10.44 11 epitope (Lindenstrøm et al., 
2014). Limited antigen presentation by infected cells could explain why TB10-
specific CD8+ T cells undergo selection and clonal expansion and could be 
detrimental for memory T cell responses in tuberculosis. First, it is unknown 
whether current vaccine strategies elicit T cells of sufficient avidity to recognize the 
sparse antigen presented by infected cells. Second, memory T cells generated by 
vaccination may drop out of the response to infection if they require a higher 
antigen threshold for activation, independent of TCR affinity (Mehlhop-Williams 
and Bevan, 2014). Why are class I MHC antigens poorly presented? In the case 
of TB10.4, the abundance of the protein in infected cells may be limiting. 
Alternatively, Mtb infection may inhibit class I MHC antigen presentation or infected 
macrophages in the lung may not be able to cross-present Mtb antigens. 
Remarkably, there exists little published data showing the direct recognition of Mtb-
infected macrophages by CD8+ T cells (Lewinsohn et al., 2006; Serbina et al., 
2000). Transfer of activated TB10Rg3 and TB10Rg4 CD8+ T cells to 
immunocompromised mice confers protection against Mtb in a TAP1-dependent 
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manner (Nunes-Alves et al., 2015). We conclude from these data that infected 
macrophages present the TB10.44 11 epitope in vivo. Although our current data 
demonstrate TCR selection, whether TCR avidity affects recognition of Mtb-
infected macrophages and bacterial killing remain to be determined. 
An important question is whether this idea of a low antigen state can be 
generalized to other antigens. We previously studied memory CD8+ T cells elicited 
by vaccination with a recombinant vaccinia virus (rVV, strain WR) expressing the 
Mtb antigen, EspA (Rv3616) or TB10.4 in BALB/c mice (Woodworth et al., 2011). 
Two weeks after Mtb challenge, the numbers of EspA- and TB10.4-specific CD8+ 
T cells were significantly greater in the lungs of vaccinated mice compared to 
control mice, indicating a successful recall response. However, there were no 
differences in the numbers of TB10.4- or EspA-specific CD8+ T cells in vaccinated 
vs. control mice four weeks after Mtb challenge. Thus, despite using a different 
vaccination strategy (rVV) and different antigens (EspA, TB10.4), we observe 
similar results, namely that memory CD8+ T cell responses are less fit than primary 
CD8+ T cell responses. Furthermore, the decreased fitness of TB10.4-specific 
memory CD8+ T cells is not solely a consequence of the peptide/CD40/poly(I:C) 
vaccination strategy. The limited antigen recognition by Ag85b-specific CD4+ T 
cells (Bold et al., 2011; Egen et al., 2011; Grace and Ernst, 2015) and the transient 
benefit of antibiotic-induced memory (Jung et al., 2005; Kamath and Behar, 2005) 
suggest relevance beyond CD8+ T cells.  
Rational vaccine design should aim to elicit protective T cells by optimizing 
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their action on infected cells in several ways: Vaccine-elicited memory T cells must 
rapidly expand and generate secondary effector T cells that undergo sustained 
proliferation following activation. Whereas the functions of primary effector T cells 
are heterogeneously expressed, vaccination can lead to more homogenous 
expression of effector functions during the recall response which may have a 
greater protective potential. Primed effector and memory T cells should efficiently 
traffic to sites of infection, but the kinetics of the response must be balanced with 
respect to T cell subsets and limit the potential for T cell exhaustion, excessive 
inflammatory pathology or an ineffective or an ineffective response that hinders T 
cell-target contact.  
As memory T cells are a potent arm of adaptive immunity, impairing memory 
T cell function becomes a plausible step in the bacterium’s evolution as a 
pathogen. This complicates vaccine development against TB, as a successful 
candidate may need to generate high affinity T cells in order to compete with naïve, 
or vaccine-elicited, lower affinity T cells during TB. If a vaccine were to 
preferentially stimulate high affinity T cells, we predict that such T cells would be 
more fit during Mtb challenge. Although some argue that generating central 
memory T cells should be the goal of vaccination against Mtb (Lindenstrøm et al., 
2013; Vogelzang et al., 2014), we and others argue that generating resident 
effector memory cells may be more important (Hansen et al., 2011; 2013; Jameson 
and Masopust, 2009; Stary et al., 2015), as CD8+ T cells residing at the site of 
infection may be poised to initiate an earlier response. Screening known Mtb 
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antigens for their ability to induce early memory T cell expansion during infection, 
and focusing on vaccines that generate high affinity T cells specific for those 
antigens could be an important next step in rational TB vaccine design. 
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